Stockwinners Market Radar for April 11, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:32 EDT Cathie Wood's ARK Investment bought 76.6K shares of Roku today

18:24 EDT Alamos Gold announced groundbreaking for Island Gold Mine expansion - Alamos Gold "announced the groundbreaking for the Island Gold Mine expansion. Already one of the most profitable mines in Canada, the expansion will increase production, lower costs, and be an economic engine for the Algoma region."

17:53 EDT Grove announces Sergio Cervantes joins as CFO - Grove Collaborative, announced Sergio Cervantes has joined the Company as Chief Financial Officer. Cervantes comes to Grove with significant financial executive experience in global consumer products, including 18 years with Unilever and four years at Gillette. During the past six years, Cervantes served as CFO of Murad, a high-end skin-care brand that was acquired by Unilever in 2015. At Murad, Cervantes led the post-acquisition integration into Unilever's Beauty and Personal Care Prestige division and implemented operational and financial efficiencies that drove both sales growth and profit improvement. In June 2021, Cervantes took on the additional role of Acting CEO of Murad.

17:49 EDT New Fitbit feature makes AFib detection more accessible - The Fitbit team blogged in part, earlier on Monday: "Fitbit received clearance from the U.S. Food and Drug Administration for our new PPG, orphotoplethysmography, algorithm to identify atrial fibrillation, AFib. The algorithm will power our new Irregular Heart Rhythm Notifications feature on Fitbit. You've got rhythm, but is it irregular? AFib is a form of irregular heart rhythm that affects nearly 33.5M people globally, and individuals with AFib have five times higher risk of stroke. Unfortunately, AFib can be difficult to detect as there are often no symptoms and episodes can come and go. Our new PPG AFib algorithm can passively assess your heart rhythm in the background while you're still or asleep. If there's anything that might be suggestive of AFib, you'll be notified through our Irregular Heart Rhythm Notifications feature - allowing you to talk with your healthcare provider or seek further assessment to help prevent a significant medical event, such as stroke." Reference Link

17:31 EDT Regeneron general counsel sells $3.7M in common stock - In a regulatory filing, Regeneron disclosed that its General Counsel Joseph Larosa sold 5.1K shares of common stock on April 7th in a total transaction size of $3.7M.

17:22 EDT SentinelOne holder Third Point sells $51.8M in common stock - In a regulatory filing, SentinelOne disclosed that Daniel Loeb's Third Point sold 1.5M shares of common stock on April 7th in a total transaction of $51.8M, reducing its stake from 16.6% to 12.0%.

17:01 EDT Redwire says it is in compliance with NYSE, SEC reporting requirements - Redwire Corporation announced that it filed its Annual Report on Form 10-K for the year ended December 31, 2021, with Securities and Exchange Commission. With this filing of the Form 10-K and the filing on April 1, 2022, of the company's Quarterly Report on Form 10-Q for the period ended September 30, 2021, Redwire is now current in its SEC filings. In addition, Redwire has received written notification from the New York Stock Exchange that it is in full compliance with the NYSE continued listing standards and was removed from the late filers' list on the Listed Standards Filing Status page.

16:47 EDT Biodesix director Strobeck buys $1M in company shares - Biodesix director Matthew Strobeck disclosed in a filing that he had purchased 558,659 shares of company stock at $1.79 per share on April 7 for a total transaction amount of $1,000,000.

16:32 EDT W&T Offshore general counsel Shahid Ghauri to leave the company - W&T Offshore announced that Shahid Ghauri, W&T's VP, general counsel and corporate secretary is leaving the company to pursue other personal interests. Nadege Assale, who has served as assistant general counsel for the past two years, will assume the role of acting general counsel until Ghauri's successor is named. Ghauri will remain with W&T through April 22 to assist in the transition.

16:24 EDT Vimeo reports revenue growth for March 18% YoY - Reports March subscribers up 6% and March Avg revenue per User or ARPU up 10% YoY. Reference Link

16:20 EDT Cohen & Steers reports preliminary AUM of $102.1B as of March 31, 2022 - Cohen & Steers reported preliminary assets under management of $102.1B as of March 31, 2022, an increase of $3.2B from assets under management at February 28, 2022. The increase was due to market appreciation of $4.1B, partially offset by net outflows of $593M and distributions of $300M.

16:17 EDT Grid Dynamics expands European presence, ceases operations in Russia - Grid Dynamics announced it has opened new offices in Zug, Switzerland, and Yerevan, Armenia. "I'm excited for Grid Dynamics expanding its presence to Switzerland. The company's engineering talents will find matching standards and values here. We also gain immediate access to the DACH region, which will, in turn, contribute to Grid Dynamics' thriving in Western Europe," said Patrick Nicolet, Director of Grid Dynamics. Grid Dynamics also announced today it would cease remaining operations in the Russian Federation in the coming weeks. The exit plan has been in the works since the Russian invasion of Ukraine in late February. The plan includes the safe and expedient relocation of willing employees and ongoing management of projects to eliminate delivery impact to clients. A majority of employees have already relocated to various engineering centers.

16:17 EDT Janssen announces research collaboration with Bioasis - Bioasis announced that it has entered into a research collaboration with Janssen Biotech, one of the pharmaceutical companies of Johnson & Johnson. Under the terms of the agreement, Janssen will have the option to research, develop and commercialize novel products based on Bioasis' xB3TM platform. The agreement was facilitated by Johnson & Johnson Innovation.

16:14 EDT Nabriva Therapeutics enrolls first patient in Xenleta trial - Nabriva Therapeutics announced that the first patient was enrolled in a Phase 1 clinical trial to assess the safety and pharmacokinetics of oral and intravenous Xenleta in adult patients with cystic fibrosis.

16:13 EDT SeaSpine announces commercial launch of Reef TA Interbody System - SeaSpine announced the full commercial launch of the Reef TA Interbody System.

16:12 EDT Golub Capital announces $306.3M in new middle-market originations in Q2 - Golub Capital announced that it originated $306.3M in new middle-market investment commitments during the three months ended March 31. Approximately 94% of the new middle-market investment commitments were one stop loans, 2% were senior secured loans and 4% were equity and other securities. Of the new middle-market investment commitments, $293.6M funded at close. Total investments at fair value are estimated to have increased by approximately 5.1%, or $262.6M, during the three months ended March 31, after factoring in debt repayments, sales of securities, net fundings on revolvers and net change in unrealized gains.

16:10 EDT Compass Minerals provides Q2 snow data and salt segment sales update - Compass Minerals "reported above-average fiscal 2022 second-quarter winter weather activity in its North American-served market compared to the 10-year historical average. When coupled with the fiscal 2022 first-quarter activity, this resulted in a relatively average winter for the full season ended March 2022 when compared to the 10-year historical average. Eleven representative cities in the company's primary North American highway deicing service area reported a total of 114 snow events during the fiscal 2022 second quarter, which was approximately 10% above the 10-year average and approximately 14% above the prior-year comparable period. The company sold approximately 4.8 million tons of highway deicing salt products in the fiscal 2022 second quarter compared to 4.6 million tons in the prior-year period. This total includes all highway maintenance products sold in the U.S., Canada and the U.K., as well as rock salt sold to the chemical industry. Sales of all Salt products were approximately 5.3 million tons in the fiscal 2022 second quarter compared to 5.0 million tons in the prior-year comparable quarter."

16:08 EDT TCG BDC changes name to Carlyle Secured Lending - TCG BDC announced that it will change its name to Carlyle Secured Lending, effective April 11.

16:06 EDT Virtus Investment reports preliminary total AUM $183.3B as of March 31 - Compared to $183.6B at February 28 and $187.2B at December 31, 2021.

16:06 EDT Eton Pharmaceuticals CFO Wilson Troutman to retire, James Gruber to succeed - Eton Pharmaceuticals (ETON) announced the appointment of James Gruber as CFO, effective immediately. He succeeds Wilson Troutman, who is retiring. Troutman will remain with the company through the end of May to ensure a transition. Most recently, he was the U.S. Controller at Horizon Therapeutics (HZNP) for seven years, where he oversaw accounting activities for the company during its rapid growth.

15:41 EDT Moody's downgrades Biogen to Baa2 with negative outlook - Moody's Investors Service downgraded the senior unsecured ratings of Biogen to Baa2 from Baa1, concluding a review for downgrade initiated on January 14. The outlook is negative. "The downgrade follows the recent finalization of a National Coverage Decision by the US Centers for Medicare and Medicaid Services that will only provide reimbursement for Aduhelm for patients in clinical trials. The commercial prospects for Aduhelm remain extremely limited, and other core products of Biogen face declining trends due to competitive pressures. Social considerations are relevant to the rating action. This is because Moody's views healthcare reimbursement policies as a key factor related to demographics and societal trends given the need for payors to effectively manage healthcare utilization. The National Coverage Decision elevates challenges Biogen faces in improving the sales of Aduhelm," Moody's stated. Reference Link

14:38 EDT Blade to provide service between LA and Indio for Festival in the Desert - Blade Air Mobility announced that it is providing helicopter, plane and jet service between Los Angeles and Indio, California over both Festival in the Desert weekends, starting at $975 per seat. Melissa Tomkiel, Blade's President, said, "This is yet another opportunity for Blade to showcase our operational excellence and unique capabilities on one of the biggest stages in pop culture. As we continue to move more people in and out of city centers around the world, we remain focused on growing our service offerings on the West Coast and at marquee events facing unique congestion."

14:13 EDT Affirm up in afternoon trading after Betaville publishes 'uncooked' rumor alert - Shares of Affirm Holdings are up $1.47, or 4%, to $39.05 after a rumor regarding Affirm was mentioned in an "uncooked alert" by Ben Harrington's Betaville blog, contacts tell The Fly. The M&A focused blog defines an "uncooked alert" as: "Market gossip as Betaville receives it. This scuttlebutt has just come in and hasn't been checked with all of Betaville's well-informed RARE sources let alone formal journalistic channels (public relations executives, bankers etc). The rumour might be total codswallop, rubbish or nonsense - but then again there may be something in it, so it's worth airing on Betaville." Reference Link

13:14 EDT Stryker says CMS grants outpatient facility code for InSpace implant - Stryker announced earlier that the United States Centers for Medicare & Medicaid Services has established a new Healthcare Common Procedure Coding System code C9781 for outpatient hospitals and ambulatory surgery centers to report the insertion of Stryker's InSpace balloon implant, effective April 1. The new HCPCS code will be used to facilitate the process of health insurance claims for individuals enrolled in Medicare and other health insurance programs, allowing for more patients to have access to care with InSpace, Stryker said in a statement. "Pursuing an HCPCS code for InSpace has been a top priority for us to enable greater access for patients and surgeons in the treatment of MIRCTs," said Matt Moreau, Stryker's Sports Medicine Vice President and General Manager.

13:05 EDT Unico American receives non-compliance notification from Nasdaq - On April 6, 2022, Unico American Corporation filed a Current Report on Form 8-K with the Securities and Exchange Commission announcing the Company's receipt of a notice from Nasdaq notifying the Company that, because its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 had not been filed with the SEC by the required due date of March 31, 2022, the Company is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1). Under the Nasdaq rules, the Company has 60 calendar days from receipt of the Notice to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company's plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-K to regain compliance. However, there can be no assurance that Nasdaq will accept the Company's plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq. If Nasdaq does not accept the Company's plan, then the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel. The notice received from Nasdaq has no immediate effect on the listing or trading of the Company's shares. However, if the Company fails to timely regain compliance with the Rule, the Company's securities will be subject to delisting from Nasdaq.

12:12 EDT Sony, Lego holding group invest $2B in Epic Games - "Fortnite" maker Epic Games announced a $2B round of funding to advance the company's vision to build the metaverse and support its continued growth. This round includes investments from existing investor Sony Group Corporation (SONY) as well as KIRKBI, the family-owned holding and investment company behind The LEGO Group, with each party investing $1B respectively. Epic continues to have only a single class of common stock outstanding and remains controlled by its CEO and founder, Tim Sweeney. "As a creative entertainment company, we are thrilled to invest in Epic to deepen our relationship in the metaverse field, a space where creators and users share their time." said Kenichiro Yoshida, Chairman, President and CEO, Sony Group Corporation. "We are also confident that Epic's expertise, including their powerful game engine, combined with Sony's technologies, will accelerate our various efforts such as the development of new digital fan experiences in sports and our virtual production initiatives." Epic's post-money equity valuation is $31.5B. The closing of the investment is subject to customary closing conditions, including regulatory approvals. Other investors in Epic Games include Tencent (TCEHY), KKR (KKR), and Disney (DIS). Reference Link

12:00 EDT Ameresco falls -10.8% - Ameresco is down -10.8%, or -$7.50 to $61.77.

12:00 EDT N-able rises 10.5% - N-able is up 10.5%, or 93c to $9.76.

12:00 EDT SailPoint rises 29.1% - SailPoint is up 29.1%, or $14.44 to $64.03.

11:51 EDT Integrated Media enters MOU with Grown Up Group for digital assets, NFTs - Integrated Media Technology announces that on April 6, 2022 the Company's subsidiary Ace Corporation has entered into a Memorandum of Understanding with Grown Up Group Investment Holdings to enter into a business relationship to be co-content developers of Non-Fungible Tokens and other digital assets for trading on the Ouction platform; to have Ace's online digital assets exchange trading market place to be one of the partners in the metaverse to be set up by GUGIHL; and GUGIHL to establish a team for the development of a metaverse. GUGIHL is initiating the development of a metaverse focusing on Asia and China culture and art. GUGIHL intends to build up a metaverse that can host events and exhibitions in the virtual world. By using these new technologies, GUGIHL expects to be able to simulate historical cultural events in the virtual world. The Company and GUGIHL agree to formalize the definitive agreement of the cooperation within 6 months from the signing of this MOU. The Parties expect the agreement will be formalized so that ACE shall have the right to supply and services GUGIHL's Metaverse, for a period of time. GUGIHL shall bear the costs of establishment and promoting the virtual galleries for a period of not less than six months from the date the Metaverse has such number of users to be agreed by the Parties. All proceeds derived/received, including advertising and gate receipts, from the virtual galleries shall be shared 50/50 between the Parties. The Parties will do best effort to find prospective themes and contents for virtual rooms in the Metaverse. Also, once GUGIHL has completed the development or acquisition of the Metaverse, Ace shall commence promoting on its Ouction platform and to its members to share/display their NFTs contents in the Metaverse. The Parties shall also find additional prospective content providers to promote the mutual interest of the Parties. The Parties will evaluate the Metaverse once available for testing and use for a reasonable test period no less than two months; the evaluation will include consumer acceptance at the Metaverse, platform performance for effectiveness, and user experience in the Metaverse virtual world.

11:17 EDT Bristol-Myers: Opdivo plus chemotherapy reduced risk of recurrence in study - Bristol Myers Squibb announced results from the Phase 3 CheckMate -816 trial, which showed that neoadjuvant treatment with three cycles of Opdivo in combination with chemotherapy significantly improved event-free survival, a primary endpoint, compared to chemotherapy alone in patients with resectable non-small cell lung cancer. With a minimum follow-up of 21.0 months, Opdivo with chemotherapy reduced the risk of disease recurrence, progression or death by 37% across randomized patients when administered before surgery. In patients receiving the combination, median EFS was 31.6 months, compared to 20.8 months for patients treated with chemotherapy alone. Additionally, while the data are still immature and the analysis did not reach statistical significance, favorable early overall survival results were observed with Opdivo in combination with chemotherapy. At two years, 83% of patients treated with neoadjuvant Opdivo and chemotherapy were alive, compared to 71% with chemotherapy alone. OS will continue to be followed for upcoming analyses. CheckMate -816 represents the first Phase 3 study with an immunotherapy-based combination to show a significant improvement in EFS, as well as in the other primary endpoint of pathologic complete response, in the neoadjuvant setting of NSCLC. Based on the EFS and pCR results from CheckMate -816, the U.S. Food and Drug Administration approved Opdivo in combination with platinum-doublet chemotherapy every three weeks for three cycles for adult patients with resectable NSCLC in the neoadjuvant setting in March 2022, and further applications are under review with health authorities globally.

11:10 EDT Vail Resorts announces affordable employee housing investments - Vail Resorts announced four investments to provide accessible and affordable housing for its employees at Park City Mountain in Utah, Whistler Blackcomb in British Columbia, Vail Mountain in Colorado, and Okemo Mountain Resort in Vermont as part of the company's strategic focus on investing in the employee experience. Collectively, the four investments will provide new affordable housing to more than 875 Vail Resorts employees, marking a more than 10 percent increase in affordable employee housing offered by the company across its resorts. At Park City Mountain Resort, Vail Resorts has entered into a five-year lease with Columbus Pacific Development which will provide an additional 441 employees with access to affordable housing in the new Canyons Village Employee Housing Development. It is located in the Canyons Lower Village adjacent to the Cabriolet lift and the Canyons Village Transit Hub. The long-term company lease begins with the 2022/23 season and has two five-year renewal options. The development is part of a public-private partnership between Canyons Village Management Association, Columbus Pacific, and Summit County, Utah. At Whistler Blackcomb, the company is pursuing the new Glacier 8 employee housing development, alongside the Resort Municipality of Whistler, which will provide an additional 240 employees with access to affordable housing. Glacier 8 will be located on Blackcomb Mountain, with easy access to Blackcomb and Whistler lifts. As a part of the investment, Vail Resorts has committed C$1M to enhance transit service to the site. The development is slated for a final Town Council vote this spring, and with approval, will move directly into the permitting and RFP process. Construction commencement is dependent on building permit issuance, which is anticipated by spring of 2023. At Vail Mountain, the company is pleased to move forward with the construction of workforce housing on the land Vail Resorts owns in East Vail, which will provide 165 employees with affordable housing. Vail Resorts will invest approximately $17 million in the project as the company seeks to address the scarcity of affordable housing in the Town of Vail. This project was approved by the Town of Vail in October 2019 after an extensive planning and environmental review, including a wildlife study performed with input from Colorado Parks and Wildlife. The approval was upheld by the district court in October 2020. Construction was then delayed due to the COVID-19 pandemic. The company looks forward to proceeding this summer with this essential project, which is expected to be complete by December 2023. At Okemo Mountain Resort, Vail Resorts is now under contract to purchase an existing property in Ludlow, Vermont, that will provide more than 30 employees with affordable housing. This $1M investment will provide long-term sustainable housing for employees and is just one mile from the resort. The purchase is subject to due diligence and expected to close in April.

11:06 EDT Vericity Inc trading halted, volatility trading pause

10:55 EDT National Vision appoints Joe VanDette as CMO - National Vision Holdings announced that Joe VanDette has joined the company as Chief Marketing Officer, reporting to CEO Reade Fahs. VanDette will be responsible for leading the organization's Marketing function including strategic brand management, CRM, advertising and media, digital marketing, e-commerce and research/insights. VanDette most recently served as Chief Marketing and Digital Executive for Smart & Final, a chain of grocery warehouse stores.

10:37 EDT Unity Rd. partners get medical cannabis establishment registration certificate - Unity Rd. announced that the brand's first partners in South Dakota have received approval from Hartford, a suburb of Sioux Falls and the state for a registration certificate to operate a medical cannabis establishment in the South Dakota Medical Cannabis Program. Local entrepreneurs, B.J. Olson and Adam Jorgensen officially broke ground on their Hartford medical cannabis establishment at 404 West Opal Lane on February 25, 2022 and anticipate the shop will open this summer. With state and city approval, the medical cannabis establishment will be one of first of three in Hartford. South Dakota residents began applying for medical cannabis patient cards on November 8, 2021, and currently there are a few hundrultaneously, Unity Rd. is assisting Olson and Jorgensen in keeping close contact with cultivators in the new cannabis market. The team anticipates that initial crops will be harvested and tested throughout the summer.

10:19 EDT Eli Lilly says ADhere data demonstrate potential for lebrikizumab - At 16 weeks, 70% of patients with moderate-to-severe atopic dermatitis, or AD, receiving lebrikizumab combined with standard-of-care topical corticosteroids achieved at least 75% improvement in overall disease severity in the ADhere trial, Eli Lilly and Company announced at the 4th Annual Revolutionizing Atopic Dermatitis, or RAD, Conference. Lebrikizumab, an investigational IL-13 inhibitor, also showed improvements in itch, sleep interference, and quality of life when combined with TCS, compared to placebo plus TCS. Among patients taking lebrikizumab plus TCS, 41% achieved clear or almost clear skin at 16 weeks compared to 22% of patients taking placebo plus TCS. At 16 weeks, 70% of patients taking lebrikizumab plus TCS achieved an EASI-75 response compared to 42% taking placebo plus TCS. Differences between patients receiving lebrikizumab in combination with TCS and placebo with TCS were observed as early as four weeks for EASI-75. Patients treated with lebrikizumab plus TCS also achieved statistically significant improvements across key secondary endpoints including skin clearance and itching, interference of itch on sleep, and quality of life measures, compared to placebo with TCS. Clinically meaningful differences were observed as early as four weeks for itch, interference of itch on sleep, and quality of life measures. Safety results were consistent with prior lebrikizumab studies in AD. Lilly recently announced 16-week data from the ongoing ADvocate studies, and an encore presentation of results was presented at RAD 2022. Additionally, longer term data from the ADvocate studies will be disclosed in coming months. "Lilly is working to empower people with skin-related diseases, such as atopic dermatitis, to live their lives to the fullest potential. We recognize the critical need for more options for people whose disease cannot be controlled with topicals. We look forward to seeing full results from our broader Phase 3 program and advancing lebrikizumab worldwide," said Lotus Mallbris, M.D., Ph.D., vice president of global immunology development and medical affairs at Lilly.

10:03 EDT GE Digital says Alliance Airlines chooses Fuel Insight for fuel efficiency - GE Digital today announced that Alliance Airlines has chosen Fuel Insight to focus efforts on saving fuel burn with fast access to flight data. The airline is building on its existing installation of GE Digital's Safety Insight solution and therefore will be able to unlock the value of the data they gather from a single software platform. Alliance Airlines has a fleet of 58 Fokker and Embraer aircraft with an additional 17 aircraft scheduled to join the fleet in 2022, providing charter, fly-in-fly-out, and wet-lease services across Australia.

10:01 EDT AssetMark appoints Christian Chan as chief investment officer - AssetMark announced it has appointed Christian Chan, CFA as Chief Investment Officer. In this role, Chan will oversee the investment management and research teams responsible for the full suite of AssetMark-managed solutions, representing $24.7B in AUM.

10:00 EDT Ameresco falls -11.1% - Ameresco is down -11.1%, or -$7.66 to $61.62.

10:00 EDT CatchMark Timber rises 7.8% - CatchMark Timber is up 7.8%, or 62c to $8.62.

10:00 EDT SailPoint rises 29.1% - SailPoint is up 29.1%, or $14.44 to $64.03.

09:47 EDT Borr Drilling falls -8.9% - Borr Drilling is down -8.9%, or -39c to $3.99.

09:47 EDT Ameresco falls -10.6% - Ameresco is down -10.6%, or -$7.37 to $61.91.

09:47 EDT Datto rises 20.4% - Datto is up 20.4%, or $5.87 to $34.59.

09:31 EDT Wipro acquires Convergence Acceleration Solutions, terms undisclosed - Wipro announced that it has acquired Convergence Acceleration Solutions, or CAS Group, a U.S.-based consulting and program management company that specializes in driving large-scale business and technology transformation for Fortune 100 communications service providers.

09:29 EDT Merit Medical receives FDA clearance for SCOUT Bx Delivery System - Merit Medical Systems has received FDA clearance for the SCOUT Bx Delivery System, the first wire-free breast localization solution that can be deployed at the time of stereotactic or MRI-guided biopsy. The SCOUT system has been utilized in nearly 300,000 breast localizations worldwide and has been referenced in more than 65 clinical publications. SCOUT is the only localization system cleared for long-term implant status for breast and soft tissue.

09:20 EDT Guardion Health announces availability of Viactiv Omega Boost Gel Bites - Guardion Health Sciences announces the availability of Viactiv Omega Boost gel bites via its branded Shopify store. The 1,200 mg Omega-3 gel bites are designed to provide total body support, including cardiovascular, brain, joint, and eye health, and can now be purchased at https://viactiv.com. Previously, the Company had only been taking pre-orders for Viactiv Omega BOOST gel bites.

09:17 EDT Sunworks launches ESG reporting program - Sunworks announced that it has launched an integrated Environmental, Social and Governance reporting program, consistent with the Company's long-term commitment to value creation through sustainable business practices. In conjunction with the launch of the program, Sunworks has developed a corporate responsibility committee, named the ESG Advisory Committee, tasked with the management of all ESG activities, which will report to a dedicated, Governance and Sustainability Board-level committee responsible for program oversight. The ESG Advisory Committee is comprised of a diverse mix of accomplished Sunworks employees from throughout the organization, ensuring that the core values of Sunworks are firmly embedded within its ESG reporting function. Sunworks expects to issue its inaugural ESG report in early 2024, prepared in accordance with established, generally accepted ESG reporting frameworks. The Company intends to issue its annual ESG report at the conclusion of an internal audit of its reported data. Beginning with Sunworks' inaugural ESG report, the Company intends to introduce measurable, multi-year targets that prioritize its sustainability objectives, with an emphasis on decarbonization and climate change, diversity and inclusion and the betterment of communities where it operates. As a provider of photovoltaic and battery-based power and storage systems for the residential and commercial markets, Sunworks provides cost-effective, sustainable powering solutions. Since 2017, Sunworks systems have generated more than 195 megawatts of low-cost, reliable solar energy, serving to significantly reduce reliance on carbon-based sources of energy generation in communities across the United States. The Company believes these systems have prevented greenhouse gas emissions totaling 939,713 metric tons of carbon dioxide equivalent.

09:16 EDT Zynex announces $10M share repurchase program - Zynex announced that its board of directors approved a program to buy back $10M of the company's common stock. The program will commence on April 12 and is scheduled to terminate on April 11, 2023 or when the $10M buyback limit is reached.

09:14 EDT Moderna appoints Jorge Gomez as CFO - Moderna, Inc., (MRNA) announced that Jorge Gomez will join Moderna as CFO, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to CEO, Stephane Bancel. Gomez joins Moderna from Dentsply Sirona, Inc. (XRAY) where he served as Executive Vice President & CFO since August 2019. David Meline, Moderna's current CFO, has decided to retire and will remain with the Company as a consultant to ensure a smooth transition of the CFO role to Mr. Gomez.

09:08 EDT WISeKey incorporates WISeKey Gibraltar - WISeKey International (WKEY) announced that it has incorporated WISeKey Gibraltar, a 100% owned subsidiary in Gibraltar (ROCK). The objective of WISeKey with the incorporation of WISeKey Gibraltar is to launch Phase II of the Gibraltar La Linea 4th Industrial Revolution Center GLL4iR.COM. Phase I was concluded with the launch of WISeSats IoT satellites with Space X. As part of Phase II of the project WISeKey Gibrlatar is set to launch a secure gateway to the metaverse from Gibraltar. The Phase II of GLL4IR.com was announced early this month during a presentation at Hassans law firm. In 2021, WISeKey announced the signing of two Memorandum of Understanding with Fabian Picardo, Chief Minister of Gibraltar and the Mayor of La Linea de la Concepcion, Juan Franco, for the development of a joint 4th Industrial Revolution Center of Excellence spearheading innovation in the region. As part of the Phase II of the project WISeKey is localizing its technology using one of the Gibraltar data center fortresses connected to the WISeKey Swiss Mountains Data Fortress. These facilities are used by cybersecurity, banking and e-gaming companies.

09:07 EDT Omnicom announces partnership with Firework - Omnicom Group announced a partnership with Firework, the world's largest livestream commerce and shoppable video platform provider. The partnership will give clients across all Omnicom agencies access to Firework's enterprise suite of proprietary short-form video and livestreaming technology, delivering shoppable livestreaming video directly to brand websites.

09:06 EDT Inspirato announces 2023 luxury cruise program - Inspirato Incorporated announced its 2023 "Inspirato Only" luxury cruise program featuring eight custom voyages spanning five continents. The Company also announced that the new slate of cruises, which represents a significant expansion of the Company's 2022 cruise program, resulted in record-breaking bookings from Inspirato subscribers in its first 24 hours of release. This included more than $3 million of reservations in the first 24 hours and immediate sell-outs of the new Greek Isles Yacht Cruise and Egypt and The Nile River Cruise.

09:05 EDT Grove's SaaS ad tech platform partners with Maropost - Interactive Offers, wholly owned subsidiary of Grove, announces a partnership with Maropost, a marketing automation and eCommerce platform, to provide an easy solution for newsletter publishers to monetize the emails they send to subscribers. When the ad unit is installed in the email, Interactive Offers will programmatically place ads that yield the newsletter the highest earning opportunities while producing ROI for the advertiser each time a person opens an email. This joint partnership creates a revenue opportunity for all parties involved, with Interactive Offers serving more targeted ads and Maropost retaining and acquiring new users by offering in-email, programmatic monetization. Grove CEO, Allan Marshall commented, "Since the acquisition, we've been focused on building out our programmatic ad technology, Interactive Offers. This marks a significant step forward with our Maropost partnership. It opens the door to a list of publishers across multiple industries and gives advertisers an easy way to monetize their lists."

09:05 EDT Zoom Video announces new education features - Zoom Video Communications announced, at the CoSN2022 national conference, new features for education in response to requests from teachers and administrators. These features span Zoom's Chat and Meetings offerings and are designed to support teachers who need to engage and manage students joining class remotely or submitting homework assignments. Chromebooks are a popular choice for students and teachers. Virtual background and blur are now available for Zoom for Chrome Progressive Web Application users. Zoom developed this capability after requests from various education customers, including Clayton County Public Schools, one of the 100 largest school districts in the United States, serving more than 52,000 students in Georgia. Breakout Rooms, a popular education feature, also received enhancements in this latest release. Program Audio allows meeting hosts to share content with audio to Breakout Rooms, adding the ability to share videos with audio. With the LTI Pro integration enhancement, educators can populate Breakout Rooms from the course roster. This can be used to assign Breakout Rooms in advance, then automatically sort students into Breakout Rooms. Other new features include sending audio and video messages into Zoom Chat, and the ability to rename participants in the Waiting Room. Asynchronous video allows users the time to consider their responses and then record as needed to provide thoughtfully crafted responses. Users can click "video" at the bottom of the chat client and record up to a 3-minute video message that goes directly into the out-of-meeting chat channel. This is useful for situations such as students submitting brief video assignments. Renaming participants before they join the meeting can be useful for attendance taking where students may be using shared devices, for creating an anonymous student group, or for affirming gender identity. Anywhere Polls will allow polling content to live in a central repository that can be accessed from any meeting on an account, instead of being associated with a particular meeting. This will make it easier for instructors to reuse polls and will also be beneficial for grading. This feature will be available soon.

09:04 EDT Editas Medicine announces dosing of first pediatric patient in BRILLIANCE trial - Editas Medicine announced the administration of EDIT-101, an experimental CRISPR gene editing medicine, to the first pediatric patient enrolled in the BRILLIANCE clinical trial, which is designed to test the safety of EDIT-101 for the treatment of Leber congenital amaurosis 10, a CEP290-related retinal degenerative disorder. "Administering the experimental medicine to the first pediatric patient in the BRILLIANCE trial marks a significant milestone toward delivering on the potential of CRISPR gene editing medicines being safe and effective in treating LCA10, which often results in significant vision loss and blindness early in life," said James C. Mullen, Chairman, President, and CEO, Editas Medicine. "Currently, there are no approved treatments for LCA10, and we look forward to sharing future updates from the BRILLIANCE trial, including sharing additional clinical data, later this year." Editas Medicine initiated enrollment in the pediatric mid-dose cohort in the BRILLIANCE trial following the Independent Data Monitoring Committee endorsement based on an analysis of safety data from a clinical trial in adult patients that tested low-dose and mid-dose levels of the experimental medicine. The Company remains on track to complete testing of the pediatric mid-dose in the first half of 2022 and expects to initiate testing of the pediatric high-dose this year.

09:03 EDT RedHill Bio: Opaganib shows 'potent in vitro efficacy' against Omicron variant - RedHill Biopharma announced study results in which opaganib, a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability. Based on the new and previously announced data, opaganib's unique human host-targeted, dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of viral spike protein mutations and remain effective against Omicron sub-variants BA.2, XE and other emerging and future variants. Dr. Michael Chan, Principal Investigator, of the Centre for Immunology and Infection, said: "The results of this study showed opaganib exerting potent inhibition of Omicron SARS-CoV-2 variant viral replication in a model that we believe comes as close as currently possible to representing the Omicron clinical pathophysiological pathway. These are highly promising results that lend further weight to opaganib's hypothesized host-mediated antiviral activity and expected effect irrespective of viral variant."

09:01 EDT Toll Brothers announces Cresta Del Sol community open for sale - Toll Brothers announced Cresta Del Sol, its newest luxury home community in Star, Idaho, is now open for sale. Situated at West Beacon Light Road and North Pollard Lane, Cresta Del Sol will offer 223 luxurious single-family homes in a serene rural location just minutes from shopping, dining, and outdoor recreation. Home buyers have their choice of 22 single- and two-story home designs in four distinct collections ranging from 1,586 to 4,067 square feet, with home prices beginning in the mid-$600,000s. Home sites at Cresta Del Sol are expansive, and some are elevated to offer picturesque views of the surrounding Boise foothills.

08:54 EDT Altamira Therapeutics announces publication on in vitro Bentrio data - Altamira Therapeutics announced that the International Journal of Molecular Sciences published a peer-reviewed paper confirming the Company's positive research findings regarding the in vitro efficacy and safety of its drug-free nasal spray, Bentrio, against the SARS-CoV-2 Delta variant. The subject study, conducted by Altamira, tested the safety and efficacy of Bentrio against the Delta variant on an in vitro 3D model of the primary human nasal airway epithelium. Safety was assessed in assays for tight junction integrity, cytotoxicity, and cilia beating frequency. The study authors concluded, "The results suggest that AM-301 is safe and significantly decelerates SARS-CoV-2 replication in cell culture inhibition assays of prophylaxis and mitigation. Its physical mechanism of action, safety and efficacy, warrant additional investigations both in vitro and in vivo for safety and efficacy against a broad spectrum of airborne viruses and allergens." Separately, on March 11, the Company announced efficacy data from testing its Bentrio nasal spray in vitro against the Omicron variant of SARS-CoV-2. The IJMS article is entitled "Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia,"

08:51 EDT Australia funds Alcoa to pilot carbon-reduction tech for alumina refining - Alcoa announced that Australian governments have provided $7.7M of funding to conduct pilot trials on a new carbon reduction technology that supports Alcoa's Refinery of the Future initiative. Alcoa of Australia has received support to test electric calcination with $6.4M from The Australian Renewable Energy Agency, ARENA, and $1.3M from Western Australia's Clean Energy Future Fund, CEFF. Calcination is the final stage in the alumina refining process and uses fossil fuels, primarily natural gas, to heat alumina hydrate crystals. Electric calcination, when powered with renewable energy, has the potential to significantly reduce carbon emissions. Additionally, electrification of calciners would allow significant amounts of residual energy, currently lost in the atmosphere as steam, to be captured and reused, saving water and negating the need for stacks to vent that steam. "We are the lowest carbon intensity alumina producer in the world, and we have a technology roadmap of future-oriented research and development projects with the goal to reduce our footprint even further," said Eugenio Azevedo, Alcoa's Vice President for Continuous Improvement. "With this support from Australian governments, we are working on our vision to reinvent the aluminum industry for a sustainable future, which includes advancing projects of global significance for the aluminum

08:44 EDT Vaalco Energy announces drilling of Avouma 3H-ST development well - VAALCO Energy announced the drilling of the Avouma 3H-ST development well that was drilled from the Avouma platform in the Etame field, offshore Gabon. Highlights: Successfully drilled the Avouma 3H-ST development well with a lateral of 268 meters in high-quality Gamba sands at the top of the structure; Encountered premium Gamba sands with 28% porosity and one Darcy of permeability; Confirms extension of Avouma reservoir and is forecasted to increase the overall recovery from the field, potentially allowing for additional wells at Avouma; Currently completing the Avouma 3H-ST well with initial production expected in the next few weeks; and Following completion, the drilling program will continue with the spudding of the ETBSM-1HB ST2 development well from the Avouma platform. George Maxwell, VAALCO's CEO, commented, "With the drilling of the Avouma 3H-ST well, VAALCO continues the success of our 2021/2022 drilling campaign. We are very excited by the high-quality Gamba sands that we encountered drilling the Avouma 3H-ST well. The well confirms the extension of the Avouma field into an updip location that should lead to increased recovery at Avouma and opens the potential for additional development well opportunities. The continued success of our drilling campaign further demonstrates the quality of our premier Etame asset. We expect the well to be online in the next few weeks and will provide the market with an update when we have initial production data. Post completion we will begin drilling the next planned well on the Avouma platform, the ETBSM-1HB ST2 development well. Our focus is on continuing to execute on our strategy and delivering strong operational and financial results. We are excited about the future for VAALCO with the continued development of our interests in offshore Gabon, upside opportunities in Equatorial Guinea and the potential to integrate accretive acquisitions aimed at further strengthening VAALCO and growing shareholder value."

08:42 EDT Standard BioTools launches Hyperion+ Imaging System - Standard BioTools announced the launch of the Hyperion+ Imaging System, the new standard in high-plex spatial imaging, providing lower limits of detection as well as improved sample capacity and time to results. The Hyperion+ Imaging System provides researchers with a deep understanding of disease and response to treatment, with the ability to stratify subjects by linking high-plex data to outcomes in clinical studies. The system can process 100-plus samples per week, performing at twice the speed of the current Hyperion Imaging System, with a 1.6x lower limit of detection. This enables detection of dim markers, an advantage that can be critical for lower-expressing markers often used in translational studies.

08:41 EDT Nano Dimension moves U.S. headquarters to Greater Boston area - Nano Dimension announced the opening of its new US headquarters in Waltham, a community in the Boston metropolitan area. As part of its business plan, the Company is relocating its US Headquarters to the greater Boston, MA area. Nano Dimension will now work in closer vicinity to academic and research institutions which are key early adopters of its ground-breaking solutions for AME, PE, and Micro-AM. Nano Dimension's new facility is near the Massachusetts Institute of Technology, Harvard, and Boston University, among many other private and public universities and research-and-development labs. The office relocation also broadens the high-tech talent pool available to the Company. Nano Dimension has already brought on two industry insiders to help navigate the new landscape of academia and technology innovators. Gene Howard Weiner, a legendary veteran of the printed circuit board marketplace for decades, has been retained as a consultant through his Massachusetts firm Weiner International Associates. In addition, Dana Korf, Principal Consultant at Korf Consultancy, has signed on as Nano Dimension's new AME Standards Manager. The new headquarters will house expanded sales operations, customer support and fabrication facilities that will be used for customer open houses and continued support for the AME Academy events and local organizations. Nano Dimension retains its presence in Sunrise, Florida, as a marketing, sales support, NaNoS printing services and logistics center.

08:39 EDT E-Home Household Service enters MoU to explore acquisition of Zhongrun - E-Home Household Service announced that the Company, via its controlled subsidiary E-Home Household Service, has entered into a Memorandum of Understanding, MoU, to explore the acquisition of Zhongrun Pharmaceutical. E-Home expects the acquisition could be completed within the next two month. Pursuant to the MoU, Zhongrun is engaged in 1) Drug development: research and development of new drugs, pharmaceutical excipients, medical devices, health supplements, and consultation services. 2) Drug sales: new and special drug varieties, concentrated drug decoction pieces, proprietary Chinese traditional medicines, chemical pharmaceutical preparations, antibiotic APIs, antibiotic preparations, biological products, etc. 3) Medical equipment: Class I medical equipment, washing and nursing supplies. 4) Special food: Prepackaged food, special food for which Zhongrun has advanced office, storage and logistics self-distribution system. Wenshan Xie, Chairman and CEO of E-Home, commented: "We look forward to welcoming Zhongrun to E-Home and joining our current household services network in China, as medicine, medical care, and nursing supplies are becoming part of the big health industry and are also necessities of home life. The pharmaceutical industry has become the focus of competition among economic powers. Many countries regard the establishment of the pharmaceutical industry as a symbol of national prosperity. In this era, the pharmaceutical industry will develop more steadily, together with Zhongrun we can bring healthy food and nursing supplies through door-to-door service via our current home service network in China, which is also an effective strategy for us to expand our current market share and service capabilities in China. Entering the big health industry through Zhongrun acquisition, we could also sell drugs and health supplements to the international market from Hong Kong."

08:37 EDT MamaMancini's sells out of Original Meatballs in a Cup - MamaMancini's announced results from the highly successful launch of its new product - Original Meatballs in a Cup - quickly selling out on an initial QVC airing in March 2022 after receiving robust engagement on its social media channels. "We are pleased to report that the introduction of Meatballs in a Cup) was an instant hit with our target audience and social media community," said Carl Wolf, Chairman and CEO of MamaMancini's Holdings, Inc. "These 'comfort in a cup' quick serve, simple meals are a protein-oriented snack and dinnertime favorite - packaged in a convenient heat-and-eat container that we believe will prove popular in convenience store applications as well. Our marketing campaigns on social media continue to enhance our sales partnership with QVC's unique direct-to-consumer platform, which reaches millions of shoppers nationwide." The Company's promotional campaign announcing the launch of Original Meatballs in a Cup on Facebook received over 500,000 views, which helped drive strong sales in a live airing on QVC hosted by spokesperson Dan Mancini. The product quickly sold out and is now back ordered. Products will be back in stock with a follow-on airing to be held on April 13th on QVC, with ongoing promotion driven through continued engagement with consumers on social media.

08:36 EDT Berkeley Lights, Vestaron announce partnership to develop pesticidal peptides - Berkeley Lights and Vestaron announced a strategic partnership to advance the development of pesticidal peptides as Active Ingredients, AIs, to improve the safety and efficacy of crop protection solutions for the global food supply. In this partnership, Vestaron will use Berkeley Lights' propriety high-throughput, functional screening service to optimize the development of novel AIs with pesticidal properties that target proven receptors. "We are pleased to be working with Vestaron and leveraging our high-throughput, functional services and Berkeley Lights platform to enable new discoveries for crop protection," said Siddhartha Kadia, Ph.D., chief executive officer of Berkeley Lights. "This marks our third partnership agreement in the agriculture space in less than a year and demonstrates the furthering of our partnership strategy. Our proprietary approach to high-throughput, functional screening is applicable to a variety of sectors and applications even beyond agriculture, including antibody, therapeutic protein, and enzyme engineering for pharmaceutical, life science, and industrial products." Additional terms of the agreement were not disclosed.

08:33 EDT Milestone commences sale of CompuFlo Epidural, CathCheck Verification System - Milestone Scientific reported that, following a successful trial and evaluation, it has commenced sales of its CompuFlo Epidural and CathCheck Verification System disposables to a leading northeast medical center. The hospital has been designated as one of the World's Best Hospitals-USA by Newsweek for the fourth consecutive year. "We are honored to announce adoption of our CompuFlo Epidural and CathCheck Verification System by another leading medical center," commented Arjan Haverhals, CEO of Milestone Scientific. "This approval follows a thorough trial and evaluation, which further validates the safety and efficacy of our technology. As a teaching hospital, our tools provide residents, fellows and even seasoned physicians greater accuracy through real-time verification of epidural needle placement, as well as subsequent monitoring of catheter placement. The addition of this hospital continues to expand our nationwide footprint in the labor and delivery market."

08:33 EDT HeartCore Enterprises launches upgraded Content Management System - HeartCore Enterprises announced the launch of its revamped corporate digital marketing solution, Content Management System. The CMS is HeartCore's customer experience management platform that streamlines website operations, allowing users to easily create, manage, and modify content on websites without the need for specialized technical knowledge. The upgraded version will allow users to realize headless distribution of diversified content and centralized management of increasing Product Information Management and Digital Asset Management as a hub for all content delivery, role-based management and editing functions. Additionally, users will now be able to manage prospects, find hot leads, and support SEO initiatives through marketing automation and personalization of content.

08:32 EDT Delek Logistics unit to acquire 3Bear Delaware Holding for $624.7M - Delek Logistics Partners announced that one of its subsidiaries has signed a definitive purchase agreement for the acquisition of 100% of the equity interests of 3Bear Delaware Holding - NM, LLC, an indirect subsidiary of 3Bear Energy, LLC, related to 3Bear's crude oil and gas gathering, processing and transportation businesses, as well as water disposal and recycling operations in the Delaware Basin in New Mexico, for cash consideration of $624.7M, subject to customary closing adjustments. Delek Logistics is executing the transaction through a newly formed, wholly owned subsidiary, DKL Delaware Gathering, LLC. The acquisition is expected to result in an investment multiple of approximately 6.25 times 2023 EBITDA. This transaction is expected to be completed around mid-year 2022, subject to customary regulatory approvals.

08:30 EDT enVVeno Medical announces U.S. VenoValve patent - enVVeno Medical Corporation announced that the U.S. Patent and Trademark Office has issued Patent No. 11,285,243 titled, "Biological valve for venous insufficiency," covering the method of manufacturing of the tissue portion of the VenoValve bioprosthetic valve, the Company's lead product. The previously issued U.S. patent covers the VenoValve frame. The VenoValve is a surgically implanted currently undergoing the SAVVE U.S. pivotal trial for safety and effectiveness as a treatment of deep venous Chronic Venous Insufficiency. The VenoValve is intended to restore proper directional blood flow for patients with CVI of the deep veins of the leg. CVI occurs when the natural valves inside of the veins fail, causing blood to flow in the wrong direction, and creating increased pressure inside of the veins of the leg.

08:29 EDT RedHill Biopharma announces Omicron inhibition with opaganib - RedHill Biopharma announced study results in which opaganib, an oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability. Based on the new and previously announced data, opaganib's unique human host-targeted, dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of viral spike protein mutations and remain effective against Omicron sub-variants BA.2, XE and other emerging and future variants. Opaganib was studied in a global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia. In a prespecified analysis of all Phase 2/3 study patients with positive PCR at screening, opaganib improved the median time to viral RNA clearance by at least 4 days, achieving viral RNA clearance in a median of 10 days, while the median for clearance was not reached by the end of 14-days treatment in the placebo arm. Additional prespecified analyses in key subpopulations from the Phase 2/3 study also demonstrated a 70% reduction in mortality and a 34% benefit in time to recovery for patients treated with opaganib. Regulatory submissions and discussions in the U.S., Europe, UK and additional countries are progressing regarding confirmatory data requirements and pathways to potential approval.

08:27 EDT Diversified Energy publishes 2021 sustainability report - Diversified Energy Company is pleased to announce the publication of its 2021 Sustainability Report. The updated report, available on the Company's web site, provides comprehensive insight into Diversified's programs and progress across a range of environmental, social, and governance focus areas. The Company featured several highlights of its 2021 Sustainability Report on March 22, 2022 in its full year results release and 2021 Annual Report. Key Highlights: Expanded emissions reduction activities: Project Fresh initiative improves accuracy of emissions-producing asset inventory using measured emissions, reducing reliance on default, often much higher, theoretical factors; Deployment of 600 handheld leak detection devices enhances ability to identify and remediate unintended emissions, primarily in upstream assets; Successful pilot and expanded use of light detection and ranging aerial surveillance to detect and drive emission reductions, primarily in midstream assets. Enhanced emissions reporting and reduction commitments: Revised 2020 reported methane emissions intensity 62% lower to 1.6 MT CO2e/MMcfe; Reduced 2021 methane emissions intensity 6% vs revised 2020 to 1.5 MT CO2e/MMcfe, with opportunities to reduce further as the Company expands its Project Fresh initiatives into its Central Region; Engaged ISOS Group, Inc. to independently verify its 2021 greenhouse gas emissions, affirming the Company's IPCC-reported emissions at a moderate level II assurance in accordance with AA1000 Assurance Standard; Accelerated commitment to reduce Scope 1 methane emissions intensity 30% by 2026 and 50% by 2030; Accelerated commitment to achieve net zero Scope 1 and Scope 2 GHG emissions by 2040; Expanded alignment with the recommendations of the Task Force on Climate-Related Financial Disclosures Social program highlights: Expanded diversity initiatives with new applicant tracking system and targeted recruiting in diverse communities within the Company's operating footprint; Contributed $1 million to community outreach efforts during 2021 and committed up to $2 million in 2022, in addition to the Company's existing commitments to fund scholarships, internships and vocational training opportunities. Governance program highlights: Enhanced corporate polices for Environmental, Health & Safety, Corporate Responsibility and Human Rights; Published new, Board-approved corporate polices for Climate Change, Employee Relations and Business Partners; Increased Board diversity to ~38% female with October 2021 appointment of Sylvia J. Kerrigan, improving the Company's ranking by the FTSE Women Leaders Review; Increased the Board's climate change expertise with a growing emphasis on climate when determining capital allocation aligned with the Company's strategy.

08:23 EDT Moderna doses first participants in Phase 1/2 study of mRNA-1020, mRNA-1030 - Moderna announced the first participants have been dosed in the Phase 1/2 study of the Company's seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030. This Phase 1/2 randomized, observer-blind, dose-ranging study will evaluate the safety, reactogenicity and immunogenicity of a single dose of mRNA-1020 or mRNA-1030 in healthy adults 18 years and older in the U.S. The mRNA-1020 and mRNA-1030 candidates each include eight mRNAs, targeting both hemagglutinin and neuraminidase at different doses and ratios. Similar to Moderna's influenza vaccine candidate mRNA-1010, mRNA-1020 and mRNA-1030 will target the strains recommended by the World Health Organization for the prevention of influenza, including seasonal influenza A/H1N1, A/H3N2 and influenza B/Yamagata and B/Victoria. The Company intends to enroll approximately 560 participants in the study. Moderna is pursuing an iterative approach to influenza vaccine development, with increasing levels of enhancements aimed at improving immune responses and increasing immunologic breadth. Though currently licensed influenza vaccines target predominantly the viral HA, in the mRNA-1020/1030 trial, Moderna adds neuraminidase antigens in order to target both major glycoproteins with the aim of promoting a broad and robust antibody response.

08:21 EDT ATIF Holdings CEO purchases 25,899 shares of ATIF on open market - ATIF Holdings announced that ATIF's President, Chairman of the Board, and CEO, Jun Liu has purchased 25,899 shares of ATIF stock on the open market from January 18-April 5. Since December of 2021, Jun Liu has purchased 50,500 shares of ATIF stock in total.

08:20 EDT Trinity Biotech enters $45M strategic investment, partnership with MiCo - Trinity Biotech announced a $45M strategic investment and partnership with MiCo Ltd. MiCo, a KOSDAQ-listed and Korea-based company, is engaged in the biomedical business through its affiliate MiCo BioMed, in addition to providing cutting-edge technology driven solutions in the semi-conductor and green energy sectors. The investment consists of approximately 11.2m ADSs at a price of $2.25 per ADS, which represents an approximately 130% premium to the closing price of $0.98 on April 8, 2022. Following this investment MiCo will hold 29.9% of the voting share capital of the Company. In addition to the newly issued equity, the Company has agreed to issue a seven-year, unsecured junior convertible note in the amount of $20M, with a fixed interest rate of 1.5% and an ADS conversion price of $3.24 per ADS. This will result in a total investment by MiCo of approximately $45M. The convertible note mandatorily converts into ADS if the volume weighted average price of the Company's ADSs is at or above $3.24 for any five consecutive NASDAQ trading days. It is intended that these funds will be primarily used to repay a portion of the Company's $81.25M term loan, which is expected to reduce the Company's annual interest cost by approximately $4M each year. The Company also expects that this investment will facilitate it exploring lower cost debt funding options, in the short term, with the aim of further reducing the company's interest expense through refinancing the balance of the Company's term loan at substantially lower interest rates. The investment is subject to customary Korean central bank approvals and is expected to close before the end of April 2022. MiCo BioMed is an in-vitro diagnostics focused biotechnology company with innovative Lab-on-a-Chip and AI-based rapid point of care testing applications in various diseases that are supported by a competitive large scale manufacturing base in Korea. MiCo BioMed has a leading-edge desktop molecular PCR testing platform that has achieved impressive growth in Africa, Asia, South America, and European markets with approximately 800 placements over the past 2 years. The leadership teams from both Trinity Biotech and MiCo have identified the dramatic disruption to the diagnostic market brought about by COVID-19, with a change in diagnostic practices away from centralised lab-based testing to dispersed testing in at home and at point of care settings PoC, as leading to a need for a broader range of high quality, technology-enabled PoC and at home testing products and services to support the expected global adoption of distributed diagnostics. This strategic investment and partnership are intended to accelerate Trinity Biotech's organic and inorganic growth into one of the world's largest diagnostic companies, with a focus on innovative technology-driven PoC and at-home diagnostic products and services. Through distribution and joint development agreements, it is intended that Trinity Biotech will distribute MiCo BioMed's molecular PCR and next-generation ELISA diagnostic platforms in Trinity Biotech's core markets including North America and Western Europe - this will provide Trinity Biotech with a significant expansion of its product portfolio. In addition, it is intended that MiCo BioMed will obtain commercial rights to sell certain of Trinity Biotech's products in numerous global markets including countries within the Asia-Pacific market. The partnership is also focused on other key areas of collaboration including R&D, pan-global regulatory certifications and manufacturing synergies. In conjunction with MiCo and MiCo BioMed's strategic investment, the founder and chair of MiCo, Mr. Sun-Q Jeon, will become Chairperson of Trinity Biotech. In conjunction with the financing, Trinity Biotech is also pleased to announce a number of upcoming appointments to its Board with Aris Kekedjian and Michael Sung Soo Kim expected to join the Board once the aforementioned investment has completed. Most recently, Aris was CEO of Icahn Enterprises. Michael has held a number of senior executive positions include CEO of Hyundai Securities Asia. Current directors Kevin Tansley, Clint Severson and James Merselis will retire from the Board on completion of the aforementioned investment. Trinity Biotech will continue to be led by its senior executive team, CEO Ronan O'Caoimh and CFO John Gillard, who will both remain board members of Trinity Biotech.

08:18 EDT Hoth Therapeutics announces updates for novel cancer therapeutic, HT-KIT - Hoth Therapeutics announced a development updates for its novel cancer therapeutic, HT-KIT. Hoth's innovative approach, which employs a chemically-stable antisense oligonucleotide to target the proto-oncogene KIT through by frameshifting KIT mRNA transcripts, has potential as a KIT-targeted therapeutic alone, or in combination with agents that target KIT signaling, in the treatment of KIT-associated malignancies. Through a sponsored scientific research agreement with North Carolina State University, the team used the HT-KIT mRNA frame-shifting approach on mast cell leukemia cells in vitro and found that KIT protein expression, signaling and function were reduced. Treatment with HT-KIT prevented cancer cell growth and induced cell death over 72 hours. In a humanized mast cell leukemia mouse model, tumor growth and infiltration of other organs were reduced and tumor cell death increased when HT-KIT induced frameshifted c-KIT mRNA. Hoth has filed several patent applications to protect this IP throughout the world.

08:17 EDT MoneyLion announces Mark Torossian appointed Chief Accounting Officer - MoneyLion announced today that Mark Torossian has been appointed Chief Accounting Officer, effective April 1. Mark will oversee MoneyLion's accounting and reporting functions and report to Rick Correia, MoneyLion's Chief Financial Officer.

08:17 EDT Singularity Future Technology, Golden Mainland form bitcoin mining joint venture - Singularity Future Technology and Golden Mainland announced the formation of a Bitcoin mining site joint venture. The joint venture plans to invest up to $250M over time to build a total of 1GW of mining sites in Texas, Ohio, and other states, with capacity for up to 300,000 Bitcoin miners, each with 3,400 watts/hour in energy consumption. Singularity is a global logistics and blockchain technology company engaged in shipping, chartering, logistics services and technology services. Golden Mainland is a company engaged in the provision of electricity services in North America. Under the terms of the Joint Venture, Singularity will own 51%, and Golden Mainland will own 49%, with each party contributing capital in accordance with its ownership interest. Singularity expects to make its initial capital contribution of approximately $10 million to the Joint Venture from available cash.

08:16 EDT USPTO has issued enVVeno patent 'Biological valve for venous insufficiency' - enVVeno Medical announced that the U.S. Patent and Trademark Office USPTO has issued Patent No. 11,285,243 titled, "Biological valve for venous insufficiency," covering the method of manufacturing of the tissue portion of the VenoValve bioprosthetic valve, the Company's lead product. The previously issued U.S. patent covers the VenoValve frame."We have invested a significant amount of time and energy over the past few years in formulating and executing an aggressive strategy to build a robust patent portfolio around the VenoValve and will continue to file new patent applications both in the U.S. and around the world as we continue to execute that strategy," commented enVVeno Medical CEO, Robert Berman. "Our efforts are just beginning to yield positive results and we expect to see a significant increase in the frequency of newly issued VenoValve patents both inside and outside of the U.S."

08:15 EDT Tanger Factory raises annual dividend 9.6% to 80c from 73c per share - Tanger Factory announced that its Board of Directors approved a 9.6% increase in the annual dividend on its common shares from 73c per share to 80c per share. Simultaneously, the Board of Directors declared a quarterly cash dividend of 20c per share, payable on May 13 to common shareholders of record on April 29.

08:14 EDT INmune Bio to present data on INB03 at AACR annual meeting 2022 - INmune Bio announces data demonstrate that INmune Bio's INB03 reverses MUC4 experssion in HER2+ BC cell line, JIMIT-1, to re-establish sensitivity to trastuzumab and tyrosine kinase inhibitors, TKI. Mucin 4, MUC4, a glycoprotein is an easily measured biomarker in women with breast cancer. Previously, INmune Bio reported MUC4 expression predicts worse survival in women with HER2+ BC. Study results show this new evaluation focused on the effects of MUC4 expression on the immune cells of the tumor microenvironment in HER2+ BC. These data were presented here today at the American Association of Cancer Research Annual Meeting in 2022, held in New Orleans April 8-13. The findings of this study predict that women with MUC4+/HER2+ BC are expected to have fewer tumor infiltrating lymphocytes than women who do not express MUC4. In a nude mouse model of MUC4+HER2+ BC, the combination of INB03+traz increased the number of activated NK cells and anti-tumor macrophages in the TME. In this nude mouse model, anti-tumor macrophage function is more important than NK cell function in controlling tumor growth.

08:13 EDT Vislink to demonstrate scene-to-screen unified-workflow solution at NAB 2022 - Vislink will demonstrate its end-to-end, unified all-IP workflow solutions for live event production at NAB 2022 in Las Vegas, NV, April 23-27. Vislink and Mobile Viewpoint team members will be onsite in booth #C7508. The Quantum-LinkMatrix unified wireless camera workflow brings together COFDM wireless camera systems and bonded cellular/5G roaming camera systems into one single managed solution. By integrating the two production workflows into one video source and configuration management platform, live event production teams can efficiently manage content capture from all types of wireless systems.

08:12 EDT American Axle enters agreement to acquire Tekfor Group for EUR125M - American Axle announced that it has entered into a definitive agreement under which AAM will acquire Tekfor Group for an enterprise value of EUR125M. Based in Hausach, Germany, Tekfor Group is a specialist in automotive fasteners and metal formed components for driveline, powertrain, and E-mobility applications. Tekfor generated sales of approximately EUR285M in 2021. Subject to regulatory approval and other customary closing requirements, the transaction is expected to close in the second quarter.

08:11 EDT Moderna doses first patient in mRNA-1020, mRNA-1030 study - Moderna announced the first participants have been dosed in the Phase 1/2 study of the company's seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030. This Phase 1/2 randomized, observer-blind, dose-ranging study will evaluate the safety, reactogenicity and immunogenicity of a single dose of mRNA-1020 or mRNA-1030 in healthy adults 18 years and older in the U.S. The mRNA-1020 and mRNA-1030 candidates each include eight mRNAs, targeting both hemagglutinin and neuraminidase at different doses and ratios. Similar to Moderna's influenza vaccine candidate mRNA-1010, mRNA-1020 and mRNA-1030 will target the strains recommended by the World Health Organization, or WHO, for the prevention of influenza, including seasonal influenza A/H1N1, A/H3N2 and influenza B/Yamagata and B/Victoria. The Company intends to enroll approximately 560 participants in the study.

08:10 EDT Curis announces FDA partial clinical hold on TakeAim Lymphoma study - Curis announced that the U.S. FDA has placed a partial clinical hold on the company's TakeAim Lymphoma study. The TakeAim Lymphoma study is a Phase 1/2 open-label dose escalating clinical trial investigating emavusertib in patients with B-cell malignancies. This week's notification extends the partial hold across both studies. This is not unexpected, as both studies treat patients with emavusertib. And, as previously announced, the company had already voluntarily paused enrollment in the TakeAim Lymphoma study in connection with its announcement on April 4, of the FDA's partial clinical hold on the TakeAim Leukemia study. "We reiterate our previous comments: we are committed to ensuring the safety of patients in our studies and to working collaboratively with the FDA to develop therapies that meaningfully improve and extend patients' lives," said James Dentzer, CEO of Curis. "Given the clinical profile of emavusertib observed to date, we are hopeful that the study can be resumed soon, after appropriate review. We continue to be confident in the potential of emavusertib to address the high unmet need of patients with B-cell cancers, AML, or MDS."

08:09 EDT OncoCyte presents data for DetermaIO at AACR annual meeting 2022 - Oncocyte will present data at the American Association for Cancer Research, AACR, Annual Meeting 2022. The data is from a real-world cohort of patients with bladder cancer or metastatic urothelial cancer, mUC, and confirms the association of results from the Company's DetermaIO test with response to treatment with immune checkpoint inhibitors, ICI. Notably, this is the second independent mUC cohort to show the capability of DetermaIO to identify ICI responders using the same algorithm and threshold previously established and validated in bladder and other tumor types. The poster presented, titled "Confirmatory study of the IO Score, a tumor immune microenvironment, TIME, classifier, demonstrates efficacy in a real-world cohort of metastatic urothelial cancer patients treated with immune checkpoint inhibitors," sought to confirm results from the IMvigor210 trial and identify a more accurate predictor of response to ICIs in mUC to better direct patients to appropriate therapy earlier in treatment. Investigators met both objectives, confirming the IMvigor210 trial in a real-world cohort of patients with mUC and showing that DetermaIO is independent and complementary to tumor mutational burden, a commonly used method biomarker, in predicting response to ICI.

08:09 EDT Simmons First National completes acquisition of Spirit of Texas Bancshares - Simmons First National Corp. (SFNC) announced that it has completed the acquisition of Spirit of Texas Bancshares (STXB), the parent company of Spirit of Texas Bank SSB, based in Conroe, Texas, effective April 8, 2022. A definitive agreement to acquire Spirit was previously announced on November 19, 2021, with Spirit's shareholders approving the transaction in February 2022. As a result of the acquisition, Spirit of Texas Bank SSB was merged into Simmons Bank, with Simmons Bank as the surviving institution. Conversion of technology systems and customer accounts for Spirit of Texas Bank SSB were completed over the weekend, with former Spirit of Texas Bank SSB branches opening under the Simmons Bank name on Monday, April 11. With the completion of this acquisition, Simmons has approximately $28 billion in assets, $14.3B in loans and $22.1B in total deposits based on data as of December 31, 2021. In Texas, the addition of Spirit will more than double Simmons' size and scale with footings totaling approximately $4.8B in loans and $4.9B in deposits based on data as of December 31, 2021, while increasing the number of branches to 57, located primarily in the fast-growing Texas Triangle. Under the terms of the definitive agreement, each share of Spirit common stock was converted into 1.0016722 shares of Simmons common stock, with cash paid in lieu of fractional shares and to cash out Spirit stock options and warrants that were outstanding immediately prior to the effective time of the merger.

08:08 EDT BigBear.ai buys analytics software provider ProModel in 'accretive acquisition' - BigBear.ai announced it has acquired ProModel , a provider of simulation-based predictive analytics software for manufacturing, healthcare, shipbuilding, and other industries. The accretive acquisition furthers BigBear.ai's commercial growth strategy with the addition of industry-leading modeling applications used by hundreds of global customers, including many Fortune 500 companies ..In December of 2020, BigBear.ai acquired ProModel Government Services, expanding the company's modeling and simulation capabilities for federal customers. With the acquisition of ProModel Corporation, BigBear.ai can now leverage these capabilities in the commercial sector to optimize decision making with improved insights into supply chains, market conditions, equipment maintenance, capacity planning, and process efficiency. "ProModel's solutions uncover new insights to improve quality and efficiency in manufacturing, distribution, and many other industries, making them a great fit for our commercial strategy," said BigBear.ai CEO Dr. Reggie Brothers. "ProModel's focus on helping organizations make better decisions faster, coupled with its unrivaled corporate culture, perfectly aligns with our vision and mission. Our AI-powered decision support technology will offer tremendous advantages to ProModel's customers. We're excited to welcome them and all ProModel employees and partners into the BigBear.ai community."

08:07 EDT BRP Group announces Richard Tallo as chief marketing officer - BRP Group (BRP) announced Richard Tallo as chief marketing officer, effective immediately. In this role, Tallo will lead marketing and communications strategy across the firm, delivering programs designed to drive profitable growth and long-term brand recognition. Tallo joins BRP from Chubb (CB) where he served as executive VP, marketing and communications.

08:06 EDT Metals Company engages Benchmark Mineral Intelligence for life cycle assessment - TMC the metals company announced that it has chosen Benchmark Mineral Intelligence to conduct an independent life cycle assessment of the environmental impacts of the Company's planned NORI-D Polymetallic Nodule Project and compare these impacts to producing the same metals from commonly used production pathways using conventional land ores. The Benchmark LCA study will investigate the potential cradle-to-gate impacts of producing important battery materials including nickel sulfate, cobalt sulfate, copper cathode, manganese silicate and an intermediate NiCuCo matte product from seafloor polymetallic nodules in the NORI-D area. These raw materials are widely used as active cathode materials for NMC and other nickel-rich cathode chemistries for lithium-ion batteries, enabling the rapid growth of electrified transport and energy storage. The study will draw upon the Initial Assessment of the NORI-D Property independently compiled by AMC in accordance with the SEC Regulation S-K in March 2021 and a range of processing plant location scenarios developed by TMC since then. The Benchmark team will also include an additional third-party verification of the NORI-D Project LCA to ensure its compliance with ISO14040 and 14044 guidelines and standards. The LCA specialists at Benchmark will draw upon their extensive global baseline impact data of battery precursor materials derived from conventional ores to produce a comparison to the NORI-D Project LCA across multiple categories including global warming potential and disruption of carbon sinks, waste, water and land use, terrestrial acidification, freshwater and marine eutrophication. Benchmark anticipates completing its comprehensive LCA for TMC in mid-Summer 2022.

08:04 EDT PowerFleet appoints Zeitunian as Chief Technology Officer - PowerFleet (PWFL) has appointed Jim Zeitunian as the company's new Chief Technology Officer, CTO. Zeitunian will report to CEO Steve Towe and focus on executing PowerFleet's Software-as-a-Service, SaaS, transformation. Zeitunian joins PowerFleet from Coupa Software (COUP), a multi-billion-dollar provider of business spend management solutions, where he served as Vice President of Engineering.

08:02 EDT Sportradar announces acquisition of Vaix Limited - Sportradar announced the acquisition of Vaix Limited. Vaix's AI technology allows betting and gaming operators to gain a personalized view of their customers, which enables them to provide a more targeted, player-friendly experience. The acquisition does not have a material impact on the Company's annual outlook for 2022, provided on March 30, 2022. For over two years, Sportradar has partnered with Vaix and incorporated its technology into its Managed Trading Services, MTS, offering. Paolo Personeni, Managing Director of Managed Betting Services at Sportradar said: "VAIX products with their Artificial Intelligence and algorithms are now being natively integrated as part of the Sportradar Sportsbook platform, enhancing our data analytics, promotions system and player personalization. All Managed Betting Services customers will enjoy a faster and simplified integration. The acquisition of Vaix is the culmination of a very important and productive partnership we have had with the company over two years." Terms of the acquisition are not disclosed.

08:02 EDT VNET Group receives $1.3333 per ordinary share buyout proposal - VNET Group announced that its Board of Directors has recently received an unsolicited preliminary non-binding proposal letter from The Hina Group and Industrial Bank Co., Ltd., Shanghai Branch, proposing to acquire all of the outstanding ordinary shares of the company for $8.00 in cash per American depositary share, or approximately $1.3333 per ordinary share. The Board cautions the company's shareholders and others considering trading the company's securities that the Board has just received the Proposal and has not made any decisions with respect to the Proposal. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that the proposed transaction or any other transaction will be approved or consummated. The company does not undertake any obligation to provide any updates with respect to the Proposal or any other transaction, except as required under applicable law.

07:55 EDT 21Vianet trading halted, news pending

07:52 EDT Dundee Precious Metals expects hearing on Loma Larga to start in April - As previously reported on February 24, 2022, the Company's drilling activities at the Loma Larga project in Ecuador were paused, pending the hearing of a constitutional protective action against the Ministry of Environment, Water and Ecological Transition. The original hearing date was deferred following the filing of preliminary motions, and the Company expects the hearing to commence this month. DPM is working closely with government ministries and local stakeholders that support the project in defending the Action, which the Company believes is without merit. In parallel, DPM continues to advance its permitting activities for the project and is receiving strong support from the government to accelerate the environmental impact assessment process.

07:49 EDT Dundee Precious Metals produces 62,900 ounces of gold in Q1 - Dundee Precious Metals announced preliminary production results from both of its mines and smelter for the three months ended March 31, 2022. The Company confirmed that all operations are on track to meet previously issued guidance for 2022. "The first quarter was a solid start to the year, with production at Chelopech and Ada Tepe in-line with guidance," said David Rae, President and Chief Executive Officer. "At the end of March, we also announced an optimized life of mine plan for Chelopech, which resulted in higher gold and copper production, and an extended mine life to 2030." Chelopech produced approximately 41,500 ounces of gold and 7.7 million pounds of copper in the first quarter. Gold production was above expectation, largely as a result of higher ore processed and higher gold recovery achieved in copper concentrate, partially offset by lower recoveries in pyrite concentrate. Copper production was slightly below plan due to lower copper grades. Chelopech is on track to achieve 2022 guidance. Ada Tepe produced approximately 21,400 ounces of gold, which was above expectations for the first quarter as a result of higher gold grade. Ada Tepe is on track to achieve 2022 guidance, with grades and production expected to be stronger in the second half of the year. The Tsumeb smelter processed approximately 47,200 tonnes of complex concentrate in the first quarter of 2022. This was below target for the quarter as a result of maintenance to the off-gas system as well as reduced baghouse capacity, which impacted throughput. Additional maintenance to both systems is expected to take place during the scheduled Ausmelt furnace maintenance, which is scheduled for the second quarter of 2022. Tsumeb is on track to meet 2022 guidance. On March 31, 2022, DPM announced a mine life extension to 2030, an optimized life of mine plan and updated Mineral Resource and Mineral Reserve estimates for the Chelopech mine. The updated LOM plan adds approximately 286,000 ounces of gold production and 47 million pounds of copper production between 2022 and 2030, relative to the previous mine plan1 reflecting higher metallurgical recoveries and improved commercial terms. DPM filed a technical report entitled "NI 43-101 Technical Report and Mineral Reserve Update, Chelopech Mine - Chelopech, Bulgaria" with an effective date of March 31, 2022.

07:46 EDT Provectus announces presentation of multiple protein kinase signaling targets - Provectus announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 for the treatment of high-risk and refractory adult solid tumor cancers is being presented at the annual meeting of the American Association for Cancer Research, AACR, being held April 8-13, 2022 in New Orleans, Louisiana. Highlights from the 2022 AACR Presentation: PV-10 delivers cytotoxic activity in vitro against a panel of high-risk and refractory adult solid tumor cell lines; PV-10 is cytotoxic at pharmacologically-relevant concentrations across all cancer cell lines; PV-10 treatment shows target modulation of key markers associated with apoptosis and autophagy induction; PV-10 targets multiple protein kinase signaling pathways, including the phosphorylation of WNK lysine deficient kinase 1; PV-10 treatment leads to consistent inhibition of WNK1 phosphorylation at the T60 site in all cancer types based on protein kinase profiling of PV-10-treated cancer cells compared to vehicle-treated cells; PV-10 treatment inhibits the migration of cancer cells similar to pan-WNK inhibitor WNK463 in different head and neck cancer cell lines. Dominic Rodrigues, Vice Chair of Provectus' Board of Directors, said, "WNK1 is recognized as an inhibitor of autophagy and a promoter of cancer cell proliferation, migration, and invasion in breast cancer, glioblastoma, and non-small cell lung cancer. WNK1 potentially regulates important oncogenic pathways, including Wnt signaling by controlling beta-catenin levels. We are grateful to Dr. Narendran and his University of Calgary team for their many discoveries related to PV-10 cancer treatment, including now identifying multiple, specific, actionable drug targets."

07:43 EDT Context Therapeutics announces data from two programs at AACR - Context Therapeutics announced encouraging preclinical data from two pipeline programs. The data are being presented at the American Association for Cancer Research, AACR, Annual Meeting 2022. Summary of Data Presented: ONA-XR: Title: Targeting progesterone receptor with the antiprogestin onapristone in patient-derived xenograft models of estrogen receptor positive, PR positive bone metastasis of breast cancer." This study evaluated the efficacy and safety of ONA-XR in combination with fulvestrant, palbociclib, or alpelisib in different PDX models established from ER+ and PR+ breast cancers. Anti-tumor activity combination of ONA-XR with fulvestrant, palbociclib, or alpelisib was significantly increased compared to monotherapy, while triple therapy resulted in tumor regressions in the majority of xenografts. Title: "Progesterone promotes immunomodulation and tumor development in the murine mammary gland." This study investigated whether progesterone and PR drive immunomodulation in the mammary gland and promote tumor formation. Syngeneic mammary gland tumor models were utilized to evaluate the effect of P4 on the growth of PR+ mammary gland tumors in vivo, which revealed that P4 promoted tumor growth and decreased immune cell infiltration of PR+ mammary gland tumors. Title: "PR/STAT3 nuclear transcriptional complexes mediate aurora-A kinase-induced stemness plasticity in ER+ breast cancer." This study evaluated the role of PR in mediating the AURKA/STAT3 oncogenic signaling axis, which is associated with cancer cell plasticity and resistance to endocrine therapy, including CDK4/6 inhibitors. A novel mechanism was identified wherein AURKA-induced stemness plasticity is mediated through the activation of phosphorylated PR transcriptional complex that regulates the expression of KLF4 stemness reprogramming gene. CLDN6xCD3 Bispecific Antibody: Title: "Atomic-level specificity of Claudin 6 monoclonal antibodies isolated for treating solid tumors." This study identified monoclonal antibodies targeting oncofetal protein Claudin 6. Despite their potential as cancer therapeutics, a limited number of CLDN6 monoclonal antibodies are in development because MAbs with high affinity and specificity for CLDN6 are difficult to isolate. Title: "Development of claudin 6 bispecific antibodies for treatment of ovarian cancer." This study evaluated a large set of CLDN6xCD3 bispecific antibodies using multiple formats and CD3 arms that encompass different valencies and geometries. The panel of bispecifics was functionally tested in in vitro T cell cytotoxicity assays cells and demonstrated potent killing of CLDN6-expressing cells with minimal killing of cells expressing other closely related claudin family members.

07:39 EDT Vitalhub announces multi-year regional licensing contract with NHSEI - VitalHub announces a multi-year regional licensing agreement of subsidiary Transforming Systems, TS, SHREWD suite of solutions with NHS England and NHS Improvement Midlands, NHSEI. This transaction marks a new customer sale for the Company, with TS having engaged with NHSEI since July 2021. The Customer, NHSEI, provides care for a population of 10.5 million people. The sale includes licensing access to Transforming Systems SHREWD Platform, SHREWD Region, and SHREWD Vantage products. Use of these solutions by the Customer is anticipated to deliver a host of operational benefits, improving organizational efficiency, coordination and delivery of care. Specific benefits include, simplifying operational view of real-time regional pressures, standardizing reports across regions, reducing administration for reporting end users, promoting consistent and timely onward reporting, providing data driven information for improved analysis, reducing interruption to operational activity by removing need to manually gather operational data, streamlining processes for the regional oversight body, enabling oversight of capacity and demand to inform conveyancing decisions in real time, improving patient safety and reduced patient risk, and overall improvements to care for the population of the Midlands. "This sale to NHS England and NHS Improvement Midlands marks one of the largest regions to have licensed the Transforming Systems solutions," said Dan Matlow, CEO of VitalHub Corp. "We are delighted to support this region through providing access to our SHREWD suits of offerings. We view this sale as continued ratification of the market demand for our products, and the market leadership we have established and continue to maintain within the UK healthcare landscape, and beyond."

07:37 EDT GeoPark announces Q1 consolidated oil and gas production 36,626 boepd, up 6%

07:37 EDT ProAssurance : Executive Chairman W. Stancil Starnes to retire from board - ProAssurance announced that W. Stancil Starnes, Executive Chairman of the Board of Directors, will retire from the ProAssurance board at the end of his current term and is not standing for re-election. Mr. Starnes will serve his remaining term as a director and Executive Chairman, which expires at the Annual Meeting Shareholders to be held on May 24th.

07:36 EDT Worlds Inc. partners with CrossTower for NFT marketplace services - Worlds Inc. announces a partnership with CrossTower. Worlds will utilize CrossTower's global non-fungible token marketplace and services to sell NFTs of digital art, avatars, and other artifacts related to the first online interactive virtual worlds created for some of the most famous music and entertainment artists and brands, such as Aerosmith, David Bowie, New York Yankees, DMC, WWE, and Coca-Cola. Worlds and CrossTower will soon announce rare and exclusive NFT drops that will be available to users at https://crosstower.com/nft. Unique benefits of the CrossTower NFT marketplace platform: Minting and white glove services for creators: CrossTower's marketplace offers facilities like minting, trading and drop. The marketplace also offers compliance friendly consulting services for NFT creators - helping with complex procedures, and providing tiered advisory services, taking them from ideation to actualization. Exclusive collections for collectors: Buyers and collectors can access authentic and exclusive collections on the marketplace. A seamless, elite experience for traders: Traders can participate in auctions to collect rare artwork. CrossTower's marketplace provides a seamless resell experience, offering NFT purchases in ETH. Eventually, CrossTower plans to integrate multichain capabilities.

07:35 EDT Guardian Group selects Sapiens' customer acquisition solution - Sapiens announced that Guardian Group is integrating Sapiens' customer acquisition solution for their life and health operations. Sapiens IllustrationPro and Sapiens ApplicationPro will be deployed in Guardian's Share Services organization, providing a cohesive user experience across Guardian's three carriers, including Guardian Life of the Caribbean Ltd., Fatum and Guardian Life Ltd. The platform features flexible branding and omni-channel integrations to cater to the agent experience to provide a next generation quoting and illustration system to improve how Guardian can present their offering in a clear and concise manner to improve their closure rate. Also, the integration of IllustrationPro and ApplicationPro to Guardian's UnderwritingPro will provide a straight-through processing and auto decision environment to decrease their time to issue.

07:34 EDT AnPac Bio, Hunan Weitou sign $15M equity investment - AnPac Bio-Medical Science announced that on April 4, 2022, the Company and Hunan Weitou Technology have signed a legally binding equity investment totaling $15M which will be invested in five installments over the next 30 months. Under the terms of the agreement, the new investor will invest $3M at the beginning of every 6 months. The first $3M, which is in the form of private equity investment, has a purchase price at $0.414 per share. It is expected that the first investment installment will be completed in April 2022.

07:32 EDT CTO Realty Growth announces $30M preferred investment in Watters Creek - CTO Realty Growth announced it has entered into a preferred equity agreement to provide $30M of funding towards the acquisition of the Watters Creek at Montgomery Farm grocery-anchored, mixed-use property in Allen, Texas. Watters Creek at Montgomery Farm is approximately 458,000 square feet of grocery-anchored retail and office, anchored by Market Street, Anthropologie, Mi Cocina, DSW, The Cheesecake Factory, Brio Italian Grille, and Michaels, and includes a variety of national and local retailers and restaurants. The three-year Preferred Investment for the acquisition of the Property was fully funded at closing. The Preferred Investment is interest-only through maturity, includes an origination fee on the total Preferred Investment, and bears a fixed preferred return above the range of the Company's guidance for initial investment cash yields.

07:24 EDT Goodbody Health's PhytoVista granted UK Home Office controlled drugs licence - Goodbody Health announced that its subsidiary, PhytoVista Laboratories, has been granted a controlled drugs licence that allows the company to handle up to Schedule 1 Controlled Drugs. This comes as the UK authorities look to the regulation of the UK consumer cannabinoid product testing infrastructure ahead of wider compliance within the industry. The FSA have released the list of products associated with a credible Novel Food application and we expect the industry to continue to move to a fully regulated market that the Consumer can trust. PhytoVista is one of a small number of laboratories accredited by the UK National Accreditation Service with extended provisions to carry out these specialist activities.

07:23 EDT NeoGenomics expands strategic partnership initiatives with Biognosys - NeoGenomics announced a global strategic partnership agreement with Biognosys, This partnership strengthens NeoGenomics' proteomics-based product capabilities for its Pharma Services Division from early discovery translational research through clinical trial work in oncology drug development programs. In a collaborative scientific effort, NeoGenomics and Biognosys AG have designed a multi-modality approach for the protein analysis of tumor samples from late-stage melanoma patients treated with immune-checkpoint inhibitors, demonstrating the power of a dual proteomic and multiplexed immunofluorescence profiling for a comprehensive characterization of melanoma patients along with discovery and detection of markers for predictive response to ICI-therapy. The collaboration combines Biognosys' TrueDiscovery unbiased proteomics platform based on proprietary mass spectrometry technology with mIF spatial tissue analysis using MultiOmyx, a NeoGenomics proprietary platform. This data will be presented with two posters by NeoGenomics and Biognosys at the American Association for Cancer Research, held this year at New Orleans, LA, April 8-13. The Global Strategic Partnership between NeoGenomics and Biognosys AG will encompass multiple strategic and commercial initiatives including NeoGenomics' labs offering access to Biognosys proteomics platforms, medical and scientific affairs-joint presentations and discussions along with global scientific and technical initiatives.

07:21 EDT CureVac and GlaxoSmithKline in pandemic preparedness contract with Germany - CureVac (CVAC ) announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of a maximum of two years, the contract grants the German federal government access to CureVac's manufacturing capacity until 2029, enabling rapid availability of 80 million mRNA-based vaccine doses during the remainder of the current pandemic or in future infectious disease outbreaks. By reserving this manufacturing capacity, the tender seeks to mitigate risks associated with potential supply bottlenecks in a pandemic situation. Under the contract, the federal government will pay CureVac and GSK (GSK) an annual standby fee after successful completion of the setup period, which requires the companies to maintain manufacturing capacity at constant readiness. By ensuring the availability of manufacturing capacities in Germany, the arrangement will significantly contribute to strengthening pandemic preparedness."Over the last two years, our social and economic lives as well as global healthcare systems and medical supply infrastructures were severely challenged by the COVID-19 pandemic," said Dr. Franz-Werner Haas, Chief Executive Officer of CureVac. "This underscored the importance of having access to innovative technology platforms, such as mRNA technology, as well as corresponding robust manufacturing capacities to rapidly develop and deliver life-saving vaccines - particularly as a protective measure in case of future infectious disease emergencies. Considering the unpredictable and variant-driven course of the COVID-19 pandemic, we are fully committed to safeguarding public health today and into the future."

07:21 EDT G Mining Ventures begins trading on OTCQB Market - G Mining Ventures announced that effective April 11, 2022, it has obtained approval for trading on the OTCQB under the symbol "GMINF". It is anticipated that the posting of GMIN's shares on the OTCQB will provide greater liquidity and a more seamless trading experience for U.S. shareholders. GMIN's common shares will continue to trade on the TSX Venture Exchange under the symbol GMIN. Louis-Pierre Gignac, Chief Executive Officer and President, commented, "We are excited about GMIN's official admission to the OTCQB Venture Market. Trading on the OTCQB will make the Corporation accessible to a much broader range of U.S. investors and assist in our goal of increasing liquidity and visibility in the U.S. We look forward to introducing a broader audience to our Tocantinzinho project." The permitted Tocantinzinho Project, is located in Para State, Brazil. Tocantinzinho is an open-pittable gold deposit containing 2.0 million ounces of reserves at 1.3 g/t. The deposit is open at depth, and the underexplored 688km2 land package presents additional exploration potential.

07:20 EDT Actinium Pharmaceuticals reports HER3-ARC, CD47 therapy data at AACR - Actinium Pharmaceuticals announced that preclinical data highlighting the efficacy of the combination of an anti-HER3 antibody radiation conjugate and a CD47 blocking antibody immunotherapy was presented at the American Association for Cancer Research annual meeting, which is being held April 8th - 13th at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Actinium assessed an Actinium-225-conjugated anti-HER3 antibody with magrolimab, an anti-CD47 antibody being developed by Gilead Sciences, in HER3-positive preclinical models. AACR Poster Highlights: Dramatic improvement in tumor growth inhibition is observed in vivo with the Ac-225-HER3-ARC and magrolimab combination therapy compared to magrolimab alone; The combination of Ac-225-HER3-ARC and magrolimab significantly enhanced phagocytosis in HER3-positive cells compared to either single agent in vitro; Upregulation of cell surface calreticulin is observed following treatment with 225Ac-HER3-ARC in HER3-positive cell lines.

07:19 EDT Agile receives $4.7M after selling NOL tax benefits through NJEDA program - Agile Therapeutics announced the receipt of $4.7 million in net proceeds from the sale of tax benefits pursuant to the Company's participation in the New Jersey Economic Development Authority Net Operating Loss program under the New Jersey Economic Recovery Act of 2020.

07:17 EDT AIM reports data from Phase 2a study of Ampligen for treating colorectal cancer - AIM ImmunoTech announced the presentation of data from the ongoing Phase 2a clinical study at Roswell Park Comprehensive Cancer Center evaluating AIM ImmunoTech Inc. drug candidate, Ampligen as a component of treatment for colorectal cancer metastatic to the liver at the American Association for Cancer Research, AACR, Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana. Title: "Initial results of a phase II study evaluating a chemokine-modulatory (CKM) regimen in patients with colorectal cancer metastatic to the liver." This early Phase 2a trial studied how well celecoxib, recombinant interferon alfa-2b, and Ampligen work in treating patients with colorectal cancer that has spread to the liver. For the study, recurrent/metastatic CRC patients with unresectable liver metastases amenable to biopsy were eligible. Patients had prior treatment with fluoropyrimidine, irinotecan, oxaliplatin, and an anti-EGFR targeted therapy or contra-indication to such. Patients received IFNalpha-2b IV and Ampligen plus oral celecoxib. The primary endpoint was the change in CD8+ T-cells before Rx, with that seen post-Rx. Summary of Key Findings: The study's primary endpoint was met, evidenced by increased CD8a expression post-treatment; Saw increase in the CD8a/CD4, CD8a/FOXP3 and GZMB/FOXP3 ratios; The expression of CTL-attracting chemokines CCL5, CXCL9, and CXCL10 were increased, while expression of the Treg/MDSC attractant CXCL12 was decreased post-treatment; Median OS was 10.5 months, and the median PFS was 1.5 months; No tumor responses were seen. The treatment was well tolerated. Of all enrolled patients, adverse events were noted in 74% of patients, with the most common being fatigue. Grade 3 or higher adverse events were rare.

07:15 EDT Veru jumps 26% after 'positive' results from Phase 3 trial of oral sabizabulin - In pre-market trading, shares are up 26% to $5.47.

07:15 EDT Farmland Partners sells 303 acres of North Carolina farmland for $4M - Farmland Partners sold approximately 303 acres of North Carolina farmland to a large solar power developer for $4M on Wednesday. The company realized a net gain of nearly $2.3M, or 132%, on the disposition. The parcel was part of a 944-acre farm that FPI acquired in 2015. It will continue to rent the remaining farmland to a local farmer.

07:12 EDT Green Thumb Industries to open RISE Mankato on April 14 - Green Thumb Industries announced it will open RISE Mankato on April 14. Profits from the first day of sales will be donated to Habitat for Humanity of Minnesota. In addition to RISE Mankato, the Company has five other retail locations throughout the state, including: Eagan, Hibbing, St. Cloud, St. Paul and Willmar. Formerly known as LeafLine, each store was rebranded to RISE earlier this month. Profits from the first day of sales as newly branded RISE stores will also be donated to Habitat Minnesota.

07:10 EDT Bicycle announces interim BT8009 Phase 1 trial results at AACR - Bicycle Therapeutics announced interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC( targeting Nectin-4. The results were presented in an oral presentation on Sunday, April 10 at the 2022 American Association for Cancer Research Annual Meeting in New Orleans, LA. "Since our initial BT8009 Phase I/II trial interim results last year, we are encouraged to see BT8009's promising profile endure over time. Over the last six months, the preliminary anti-tumor findings have been confirmed, the initial responses have deepened and remained durable, and the tolerability profile remains unchanged," said Dominic Smethurst, MRCP, Chief Medical Officer of Bicycle Therapeutics. "We believe BT8009 has the potential to offer clinically meaningful differentiation compared to currently available therapies and we look forward to advancing the program once the escalation phase is complete." "As previously hypothesized, we believe that the differentiated pharmacokinetic profile of BTCs has the potential to deliver improved outcomes for patients and it is pleasing to see these clinical data mature and with it, the promise for a potentially industry-leading product profile," said Kevin Lee, Ph.D., Chief Executive Officer. "We look forward to providing additional updates on BT8009 as well as updates from our broad Bicycle oncology pipeline this year." As of March 7, 2022, thirty-seven patients have been dosed in the Phase I/II trial of BT8009. A total of twelve response evaluable urothelial cancer patients have been dosed in monotherapy cohorts of 2.5mg/m2 and 5.0mg/m2 weekly in the ongoing trial.

07:08 EDT BioNTech, Matinas enter research collaboration for mRNA-based vaccines - BioNTech SE (BNTX) and Matinas BioPharma (MTNB) announced that they have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC platform technology. The parties will closely collaborate on formulation, optimization, and in vitro testing. Under the terms of the agreement, Matinas will receive an upfront access fee to work exclusively with BioNTech, as well as additional research funding from BioNTech. The parties have also commenced discussions on a license agreement for Matinas' LNC platform technology.

07:07 EDT Elanco, Ginkgo Bioworks launch BiomEdit, a microbiome innovation company - Elanco Animal Health (ELAN) and Ginkgo Bioworks (DNA) announced the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health. Microbiome science is a rapidly growing field creating breakthroughs in animal health based on the microbial communities in animals and the surrounding environment. BiomEdit intends to discover, develop and introduce differentiated products that address some of the greatest needs for innovation in animal health, including medicated feed ingredients, nutritional health and therapeutics for livestock and pet species, as well as biosecurity technology for animal disease monitoring. Elanco will contribute intellectual property and a pipeline of ongoing programs to BiomEdit, which will be staffed with members of the former Elanco microbiome R&D team. The team brings the expertise and experience needed to build on the foundation of microbiome work started at Elanco. By leveraging foundational programs from Elanco, intellectual property from both Elanco and Ginkgo, and an experienced team, BiomEdit should be well positioned as a stand-alone company to develop and launch innovative products to address unmet needs in animal health. In addition to the assets and intellectual property contributed by Elanco and Ginkgo, BiomEdit is launching with a targeted Series A funding raise of $40M, with participation by Viking Global Investors and Anterra Capital. In exchange for their respective asset and intellectual property contributions, Elanco and Ginkgo are expected to retain approximately 40% combined proportional ownership of BiomEdit, on a fully-diluted basis, upon the completion of the Series A financing. Elanco's ownership will be in non-voting shares.

07:06 EDT NeoGenomics expands partnership with Biognosys - NeoGenomics announced a strategic partnership agreement with Biognosys, a Switzerland-based company specializing in next-generation proteomics solutions for drug discovery and development this week. In a collaborative scientific effort, NeoGenomics and Biognosys AG have designed a multi-modality approach for the protein analysis of tumor samples from late-stage melanoma patients treated with immune-checkpoint inhibitors, demonstrating the power of a dual proteomic and multiplexed immunofluorescence profiling for a comprehensive characterization of melanoma patients along with discovery and detection of markers for predictive response to ICI-therapy. The collaboration combines Biognosys' TrueDiscovery unbiased proteomics platform based on proprietary mass spectrometry technology with mIF spatial tissue analysis using MultiOmy, a NeoGenomics proprietary platform. This data will be presented with two posters by NeoGenomics and Biognosys at the American Association for Cancer Research, or AACR, held this year at New Orleans.

07:05 EDT CareDx to host session on digital solutions for transplant centers - CareDx announced it will host a lunch and learn session offering strategies and digital solutions to help transplant centers thrive in the midst of increasing volumes, changing metrics, and staff burnout, during the annual UNOS Transplant Management Forum taking place April 11-13 in Phoenix, Arizona. In addition to the CareDx lunch session, Medical City Transplant Institute in Dallas had an accepted abstract, "The Transplant Connection: Improving Process Outcomes Electronically," that demonstrated the impact of using the CareDx electronic platform, TxAccess, for referral processing. The study showed that the use of this platform resulted in many benefits including: significant time savings and error reductions in referral entries; facilitation of bi-directional electronic communication between the transplant center and the referring provider; and time and supply cost savings associated with transitioning away from paper-based communications. CareDx's popular AlloCare mobile health app was recently integrated with TxAccess to help patients connect with their referring provider and transplant center in managing the complex transplant waitlisting process.

07:04 EDT Dow Inc. takes minority stake in the Hanseatic Energy Hub GmbH - Dow Inc. announced it has signed a definitive agreement to take a minority stake in the Hanseatic Energy Hub GmbH and is working with HEH's current members to advance Germany's capabilities to import supplies of liquified natural gas, bio-liquified natural gas and synthetic natural gas through the construction of an import terminal. The HEH consortium, which now includes Dow, Fluxys, Partners Group and Buss Group, is planning to build, own, and operate an import terminal for liquified gases on Dow's Stade, Germany industrial park. This zero-carbon emission terminal is to be built by 2026 and will be co-located with Dow's facilities in Stade. Dow is contributing the land for the construction of the terminal as well as infrastructure services, off-gas heat, site services and mutual harbor use rights. With a projected regasification capacity of 13.3 billion cubic metres of natural gas per year, the import terminal supports the Joint Statement between the European Commission and the United States on European Energy Security by satisfying up to 15% of Germany's current natural gas demand. The agreement would also allow the United States to meet nearly 25% of its goal to export 50 bcm of natural gas annually to Europe by 2030. Additionally, the terminal will repurpose off-gas heat at the Dow site for the carbon emissions-free regasification of the liquefied gas back to its gaseous state.

07:03 EDT Orchard announces reimbursement agreement, to make Libmeldy available in Italy - Orchard Therapeutics announced it has reached another historic reimbursement agreement with the Italian Medicines Agency, also known as Agenzia Italiana del Farmaco, AIFA, to enable access to Libmeldy for all children with metachromatic leukodystrophy, MLD, who fall within the scope of the European marketing authorization. The news marks the second reimbursement agreement to cover all eligible MLD patients that Orchard has reached with a European market this year. "Following the February announcement of our landmark reimbursement agreement with NHS England, we are pleased that the Italian Medicines Agency has recognized the significant potential clinical benefit Libmeldy offers, granting it innovative status and agreeing to reimburse the therapy for all eligible MLD patients in the country," said Braden Parker, chief commercial officer of Orchard Therapeutics. "The momentum on our reimbursement negotiations is encouraging, as is our early progress in identifying patients in both Europe and the Middle East who may benefit from this therapy."

07:03 EDT Spectrum announces resubmitted eflapegrastim BLA accepted for filing - Spectrum announced that the resubmitted biologics license application, or BLA, for eflapegrastim has been accepted for filing. The FDA has set a Prescription Drug User Fee Act, or PDUFA, goal date of September 9. Spectrum is seeking an indication to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

07:01 EDT Ardelyx, Kyowa Kirin amend license agreement for tenapanor - Ardelyx announced that it has reached an agreement with its Japanese collaboration partner, Kyowa Kirin Co. Ltd., to amend the license agreement, originally executed in 2017, that grants to Kyowa Kirin exclusive rights to develop and commercialize Ardelyx's tenapanor for the treatment of cardiorenal diseases, including hyperphosphatemia, in Japan. Under the agreement, in consideration for a reduction in the royalty rate due Ardelyx upon net sales in Japan, Kyowa Kirin has agreed to pay Ardelyx consideration of up to additional U.S. $40M payable in two tranches, with payment due following Kyowa Kirin's filing with the Japanese Ministry Health, Labour and Welfare (MHLW) of its application for marketing approval for tenapanor and the second payment due following Kyowa Kirin's approval to market tenapanor for hyperphosphatemia in Japan. Kyowa Kirin is finalizing its Phase 3 clinical program for tenapanor for hyperphosphatemia and has disclosed its current expectation to file for approval with Kyowa Kirin in the second half of 2022 and its current expectation that it will receive a decision from Kyowa Kirin regarding its application in the second half of 2023. The royalty rate at which Kyowa Kirin will make payments on net sales to Ardelyx under the License Agreement will be reduced from the high teens to low double digits for a two-year period, and then to mid-single digits.

06:54 EDT Endeavour Silver reports Q1 production of 1,314,955 silver ounces - Endeavour Silver is pleased to report first quarter 2022 production of 1,314,955 silver ounces and 8,695 gold oz, for silver equivalent production of 2M oz. "The year is off to a strong start," stated Dan Dickson, CEO. "Operationally, Guanacevi continues to outperform production expectations and Bolanitos remains steady. Strategically, we made a significant move in January signing a definitive agreement to acquire the Pitarrilla Project, one of the world's largest undeveloped silver deposits. The addition of Pitarrilla, which is expected to close in the second quarter, significantly enhances our already attractive pipeline of growth projects, which also includes Terronera and Parral."

06:50 EDT SQZ Biotechnologies presents new eAPC preclinical data - SQZ Biotechnologies shared enhanced antigen presenting cell preclinical data demonstrating that delivery of multiple mRNAs encoding for disease-specific antigens together with immune stimulators had a synergistic effect that substantially increased killer T cells in humanized mouse models. The preclinical data, presented at the American Association for Cancer Research 2022 Annual Meeting, showed this in vivo enhancement can be seen with a variety of disease antigen mRNAs across a range of HLA types. The findings indicate the potential of the company's eAPC platform to induce a robust killer T cell response against specific diseases, and the opportunity to increase the number of patients who could potentially benefit from eAPC therapeutic candidates.

06:48 EDT International Game to acquire iSoftBet for EUR 160M in cash - International Game announced that it has entered into a definitive agreement to acquire iSoftBet, an iGaming content provider and third-party game aggregator, for approximately EUR 160M in cash. The acquisition will more than double the IGT PlayDigital content library to approximately 225 proprietary games, in addition to providing a world-class, proprietary game aggregation platform to distribute third-party games, and data-driven promotional and user-engagement tools. The acquisition is expected to be completed during the second quarter of 2022, subject to the satisfaction of customary closing conditions.

06:45 EDT SailPoint to be acquired by Thoma Bravo for $65.25 per share cash, or $6.9B

06:36 EDT Teleflex announces launch of UroLift System in Japan - Teleflex has announced the launch of the UroLift System in Japan for treating benign prostatic hyperplasia, or enlarged prostate. The UroLift System is now available for purchase, effective immediately. Teleflex previously announced reimbursement approval from the Central Social Insurance Medical Council of Japan.

06:34 EDT Veru reports 'positive' results from Phase 3 COVID-19 trial of oral sabizabulin - Veru announced positive efficacy and safety results from a planned interim analysis of the double-blind, randomized, placebo-controlled Phase 3 COVID-19 clinical trial evaluating oral sabizabulin 9 mg versus placebo in 150 hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome. The Independent Data Safety Monitoring Committee unanimously recommended that the Phase 3 study be halted early due to efficacy, and they further remarked that no safety concerns were identified. The Phase 3 COVID-19 study is a double-blind, randomized, placebo-controlled Phase 3 clinical trial evaluating oral, once-a-day dosing of sabizabulin 9 mg versus placebo in approximately 210 hospitalized moderate to severe COVID-19 patients who were at high risk for ARDS and death. Patients were randomized in a 2:1 ratio to the sabizabulin treatment group versus placebo. Patients in both treatment groups were allowed to receive standard of care including remdesivir, dexamethasone, anti-IL6 receptor antibodies, and JAK inhibitors. The trial was conducted in the United States, Brazil, Colombia, Argentina, Mexico, and Bulgaria. COVID-19 infections treated in the study included the Delta and Omicron variants. A planned interim analysis was conducted in the first 150 patients randomized into the study. The primary efficacy endpoint was the proportion of patients that died by Day 60. The prespecified primary endpoint was death at or before day 60. Sabizabulin treatment resulted in a clinically and statistically meaningful 55% relative reduction in deaths in the intent to treat population. Placebo group had a 45% mortality rate compared to the sabizabulin-treated group which had a 20% mortality rate. The secondary efficacy endpoints are still being analyzed at the time of this release. Sabizabulin treatment was well tolerated in this patient population with no clinically relevant safety observations in the sabizabulin treated group compared to placebo. The company plans to meet with FDA to discuss next steps including the submission of an emergency use authorization application. As previously disclosed, the FDA granted Fast Track designation to the sabizabulin COVID-19 clinical program in January 2022, which the company hopes will help streamline the emergency use authorization process. The company has scaled up manufacturing processes to produce commercial drug supply to address anticipated drug needs following potential FDA authorization. The company has been in discussions with BARDA and other US government agencies in an effort to secure an advance purchasing agreement of drug product for the U.S.

06:04 EDT Great Wall Capital joins co-investment in Hollysys acquisition - Great Wall Capital announced that it has joined the co-investment with Recco Control and Dazheng Group in acquiring Hollysys Automation on a non-binding basis. Recco and Dazheng issued a press release on March 21 announcing the strategic cooperation memorandum of understanding entered into among Great Wall Capital, Recco and Dazheng. At this stage, there can be no assurance that any agreement with the board of Hollysys could be reached in respect of a potential acquisition of Hollysys.

06:02 EDT China Automotive announces $5M share repurchase program - China Automotive announced that its board of directors approved a share repurchase program of up to $5M of its outstanding common shares periodically over the next 12 months. Repurchases will be made in open market transactions, at prevailing market prices not to exceed $4.00 per share through March 30, 2023, subject to applicable laws, regulations and approvals. The timing of the share repurchases will depend on a variety of factors, including market conditions. Members of the management team may make additional share purchases in addition to the company repurchase.

05:27 EDT Twitter CEO says Tesla's Elon Musk has decided not to join board - Parag Agrawal, CEO of Twitter (TWTR), stated in a tweet: "Elon has decided not to join our board. I sent a brief note to the company, sharing with you all here." In his note, Agrawal states in part that Tesla (TSLA) CEO Elon Musk has decided not to join Twitter's board, sharing: "We announced on Tuesday that Elon would be appointed to the Board contingent on a background check and formal acceptance. Elon's appointment to the board was to become officially effective 4/9, but Elon shared that same morning that he will no longer be joining the board. I believe this is for the best... Elon is our biggest shareholder and we will remain open to his input. There will be distractions ahead, but our goals and priorities remain unchanged. The decisions we make and how we execute is in our hands, no one else's. Let's tune out the noise, and stay focused on the work and what we're building." Reference Link

05:23 EDT KKR acquires UK logistics assets in Harlow from TPG, Stoford for GBP 160M - KKR (KKR) announced that Mirastar, KKR Real Estate's industrial and logistics platform in Europe, has acquired four UK logistics assets, located in Harlow, for GBP 160M from TPG (TPG) and Stoford. The four newly-built Grade A freehold assets, totaling 370,000 square feet, are located in Harlow, Greater London.

05:18 EDT ASE Technology reports March revenue $1.84B vs. $1.49B last year - Reports March ATM revenue $1.08B vs. $913M last year.

05:15 EDT BioNTech presents data from BNT211 trial at AACR meeting - BioNTech presented data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and preliminary efficacy of the company's novel CAR-T cell therapy candidate, BNT211, in patients with advanced solid tumors. The preliminary results demonstrated an encouraging safety profile and anti-tumor activity in testicular cancer patients at the first evaluated dose levels of BNT211. The data were presented in the Clinical Trials Plenary Session at the AACR Annual Meeting 2022. BNT211 is a therapeutic approach which comprises two drug products, an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6, or CLDN6, and a CLDN6-encoding CAR-T cell amplifying RNA vaccine, or CARVac, which is based on BioNTech's mRNA-lipoplex technology to improve persistence and functionality of the adoptively transferred cells.The presentation included data from 16 patients who received CLDN6 CAR-T cells at dose levels 1 and 2 alone or combined with CARVac. Tumor indications included testicular cancer ovarian cancer, endometrial cancer, fallopian tube cancer, sarcoma, and gastric cancer. Treatment with CLDN6 CAR-T alone or in combination with CARVac up to dose level 2 was well tolerated and showed encouraging signs of clinical activity. All 16 patients showed robust CAR-T cell expansion 10-17 days after infusion with cell frequencies close to 109 total counts in dose level 2. Adverse events and dose limiting toxicities were manageable; cytokine release syndromes of grade 1 and 2 and one transient occurrence of neurotoxicity grade 1 were observed. At the first efficacy assessment six weeks post infusion, 6 of 14 evaluable patients showed a partial response, and 5 patients had stable disease with shrinkage of target lesions. One patient showed no change from baseline and two patients were progressing. Responses were seen in testicular and ovarian cancer patients. At 12 weeks, 4 of the 6 patients with a partial response showed deepening and durability of responses with one patient reaching a complete response 18 weeks after infusion. All 4 testicular cancer patients in the higher dose level had disease control and three of these patients showed objective responses. In addition, one testicular cancer patient showed partial response after infusion of the lowest CAR-T dose level in combination with CARVac. Antitumor activity tended to be higher at the higher CAR-T dose and when combined with the vaccine, with 4 of 5 patients in the CARVac combination group showing a partial response.

05:09 EDT China Online Education COO Liming Zhang to resign - China Online Education announced that Liming Zhang has tendered his resignation as the company's COO due to personal reasons. His last day with the company will be May 15.

05:06 EDT Fortuna Silver Mines backs FY22 gold production view 244,000-280,000 ounces - The company said, "Fortuna reiterates its annual production guidance range of 6.2 to 6.9 million ounces of silver and between 244 to 280 thousand ounces of gold or between 369,000 to 420,000 ounces gold equivalent2 in 2022, including lead and zinc by products."